

1 **Combined Lineage Tracing and scRNA-seq Reveals Unexpected First Heart Field**
2 **Predominance of Human iPSC Differentiation**

5 Francisco X. Galdos^{1,2}, Carissa Lee¹, Soah Lee⁸, Sharon Paige^{1,3}, William Goodyer^{1,3},
6 Sidra Xu¹, Tahmina Samad¹, Gabriela V. Escobar¹, Adrija Darsha⁷, Aimee Beck¹,
7 Rasmus O. Bak⁶, Matthew Porteus^{1,5}, Sean M. Wu^{1,2,4,*}

11 ¹Stanford Cardiovascular Institute, ²Institute for Stem Cell Biology and Regenerative
12 Medicine, Stanford University, ³Division of Pediatric Cardiology, Department of
13 Pediatrics ⁴Division of Cardiovascular of Medicine, Department of Medicine,
14 ⁵Department of Pediatrics, Stanford University School of Medicine, Stanford CA
15 ⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁷ University of
16 California San Diego School of Medicine, ⁸Biopharmaceutical Convergence,
17 Department of Pharmacy, Sungkyunkwan University

22 *Correspondance:
23 Sean M. Wu, MD, PhD
24 G1120 Lokey Stem Cell Building
25 265 Campus Drive
26 Stanford, CA 94305
27 smwu@stanford.edu

31 **Keywords**

32 Cardiac Development, transcription factor, cardiomyocyte differentiation, pluripotent
33 stem cells, lineage tracing, genetic engineering

43 **ABSTRACT**

44

45 During mammalian development, the left and right ventricles arise from early
46 populations of cardiac progenitors known as the first and second heart fields,
47 respectively. While these populations have been extensively studied in non-human
48 model systems, their identification and study *in vivo* human tissues have been limited
49 due to the ethical and technical limitations of accessing gastrulation stage human
50 embryos. Human induced pluripotent stem cells (hiPSCs) present an exciting alternative
51 for modeling early human embryogenesis due to their well-established ability to
52 differentiate into all embryonic germ layers. Here, we describe the development of a
53 TBX5/MYL2 lineage tracing reporter system that allows for the identification of FHF-
54 progenitors and their descendants including left ventricular cardiomyocytes.
55 Furthermore, using single cell RNA sequencing (scRNA-seq) with oligonucleotide-based
56 sample multiplexing, we extensively profiled differentiating hiPSCs across 12 timepoints
57 in two independent iPSC lines. Surprisingly, our reporter system and scRNA-seq
58 analysis revealed a predominance of FHF differentiation using the small molecule Wnt-
59 based 2D differentiation protocol. We compared this data with existing murine and 3D
60 cardiac organoid scRNA-seq data and confirmed the dominance of left ventricular
61 cardiomyocytes (>90%) in our hiPSC-derived progeny. Together, our work provides the
62 scientific community with a powerful new genetic lineage tracing approach as well as a
63 single cell transcriptomic atlas of hiPSCs undergoing cardiac differentiation.

64

65

66

67

68

69

70

71

72

73

74

75

76

77 **INTRODUCTION**

78 The human heart is one of the first organs to develop during embryogenesis with
79 critical events in progenitor specification and differentiation occurring during the first 3
80 weeks of human gestation (Buckingham et al., 2005; Cui et al., 2019; Hikspoors et al.,
81 2022; Meilhac and Buckingham, 2018; Tan and Lewandowski, 2020). Due to ethical and
82 technical limitations in the study of human embryogenesis prior to 5 weeks gestation,
83 developmental biologists have largely relied upon animal models to study cardiac
84 development (Hyun et al., 2021; Meilhac and Buckingham, 2018). Early studies in
85 mammalian cardiac progenitor biology identified the presence of two definitive
86 multipotent progenitor populations known as the first (FHF) and second (SHF) heart
87 fields which give rise to the left and right ventricles, respectively (Cai et al., 2003; Dyer
88 and Kirby, 2009; Meilhac et al., 2004; Mjaatvedt et al., 2001; Moretti et al., 2006; Waldo
89 et al., 2001). Furthermore, early lineage tracing studies using the mesodermal
90 progenitor marker, *Mesp1*, have revealed that the early specification of these lineages
91 likely occurs during the earliest stages of gastrulation, with the FHF emerging as the
92 first wave of cardiac progenitors, followed by the SHF (Lescroart et al., 2014; Saga et
93 al., 1999; Scialdone et al., 2016). With the advent of single cell RNA sequencing
94 (scRNA-seq), these progenitor populations have been extensively characterized and
95 shown to exhibit unique transcriptional expression profiles (de Soysa et al., 2019; Hill et
96 al., 2019; Xiong et al., 2019). Moreover, scRNA-seq profiling of murine left and right
97 ventricles during early cardiac development have shown that transcriptional differences
98 can be detected up to E10.5 of murine development, suggesting that early left and right

99 ventricular development is characterized by unique transcriptional regulatory networks
100 (DeLaughter et al., 2016; Li et al., 2019, 2016).

101 While the distinct identities of the first and second heart field progenitors have
102 been well established in the murine system, the identification of these progenitor
103 populations within a human model has been severely limited by lack of access to
104 human embryonic tissues. Over the past decade, the advent of human induced
105 pluripotent stem cells (hiPSCs) has allowed for the developmental modeling of multiple
106 different embryonic lineages *in vitro* (Holloway et al., 2020; Kanton et al., 2019;
107 Karagiannis et al., 2019; Lian et al., 2013; Takahashi and Yamanaka, 2006; Yamanaka,
108 2008). In the cardiac field, small molecule-based protocols modulating WNT signaling
109 have become standard due to their remarkable efficiency at generating large numbers
110 of beating cardiomyocytes that can be utilized for disease modeling, drug discovery,
111 and the study of cellular functions (Burridge et al., 2015; Chen et al., 2016; Feyen et al.,
112 2020; Lian et al., 2013; Sacchetto et al., 2020). Several questions remain as to whether
113 hiPSC cardiac differentiations are capable of modeling early cardiac progenitor biology
114 as seen during *in vivo* mouse development (Protze et al., 2019a). Moreover, evidence is
115 lacking as to whether current hiPSC differentiation protocols give rise to FHF- and SHF-
116 derived LV and RV cardiomyocytes, respectively (Protze et al., 2019a).

117 A major bottleneck in the identification of these cell types during hiPSC
118 differentiation is the lack of lineage tracing tools that have been extensively used in
119 murine models to understand the developmental lineage contributions of progenitor
120 populations (Barnes et al., 2010; Cai et al., 2003; Meilhac et al., 2004; Moretti et al.,
121 2006; Tyser et al., 2020; Vincentz et al., 2017; Zhang et al., 2021). Early studies

122 profiling the expression of the T-box transcription factor, *Tbx5*, identified its specific
123 expression at the cardiac crescent and its role as a marker of early FHF progenitors
124 (Bruneau et al., 2001, 1999). More recently, studies using inducible CreER/LoxP
125 lineage tracing have shown the exquisite specificity of *Tbx5* to label ventricular
126 cardiomyocytes on the left but not the right, demonstrating a clear boundary between
127 cell origins of left and right ventricular cardiomyocytes during embryogenesis (Devine et
128 al., 2014). While lineage tracing tools have provided insight into the cellular
129 contributions of the FHF in mice, no lineage tracing tool is currently available for tracing
130 LV and RV cardiomyocytes in a human model system.

131 To identify FHF-progenitors and their derived cell types during hiPSC
132 differentiation, we used a CRISPR-Cas9 targeting platform to engineer a TBX5
133 expression-driven, highly-sensitive, Cre/LoxP lineage tracing system in hiPSCs that
134 contain a ventricular cardiomyocyte-specific myosin light chain-2 (*MYL2*)-tdTomato
135 fluorescent protein. By conducting a time course analysis of cardiomyocyte
136 differentiation, we identified a left ventricular cardiomyocyte predominant differentiation
137 across two distinct cell lines based on the high percentage of TBX5-lineage positive
138 ventricular cardiomyocytes (>90%). Using chemically modified lipid-oligonucleotides
139 (CMOs), we conducted multiplexed scRNA-seq assays on 12 different timepoints
140 across two independent hiPSC lines. Using differentiation trajectory analysis, we
141 compared our scRNA-seq data with murine heart field development scRNA-seq data
142 and validate the FHF origin and LV identity of cardiomyocytes generated. Finally, we
143 conduct a comparison of our scRNA-seq data with a recently published 3D cardiac
144 organoid differentiation (Drakhlis et al., 2021) and identify the greater potential of a 3D

145 system to generate SHF derived cell types. Together, our findings provide a powerful
146 new tool for human *in vitro* cardiac development studies and a validated single cell
147 expression atlas for identifying the human FHF lineage during *in vitro* hiPSC
148 differentiation.

149

150 **RESULTS**

151 **Generation of a TBX5-Lineage Tracing and Ventricular Reporter Line By**
152 **CRISPR/Cas9 Genome Editing**

153 Given the well-established role of the T-box transcription factor, *Tbx5*, as a
154 specific marker of the early FHF and left ventricular lineage (Bruneau et al., 2001, 1999;
155 DeLaughter et al., 2016; Devine et al., 2014), we engineered a fluorescent lineage
156 tracing system that would allow for the determination of whether *TBX5* lineage tracing
157 could correctly identify left ventricular cardiomyocytes using a human iPSC model of
158 cardiac differentiation. Previously, our laboratory developed an *MYL2*-tdTomato
159 construct targeting a P2A-TdTomato to the stop codon of the *MYL2* gene that was
160 validated to specifically isolate ventricular cardiomyocytes during hiPSC differentiations
161 (Chirikian et al., 2021). To construct a reporter system that could isolate left ventricular
162 cardiomyocytes, we employed a triple construct system that would allow for the
163 identification of *MYL2*-positive ventricular cardiomyocytes (**Figure 1A**). To lineage trace
164 *TBX5*-positive left ventricular cardiomyocytes (**Figure 1A**). To lineage trace
165 *TBX5* expressing cells during hiPSC differentiation, we developed two new genetic
166 constructs based on a P2A self-cleaving peptide system that allows the tethering of
167 genetic construct expression with a gene of interest (Liu et al., 2017). The first construct
168 consists of tandem P2A-Cre Recombinase genes that is targeted to replace the stop
169

170 codon of *TBX5* (**Figure 1B**). The second construct consists of a constitutively active
171 CMV promoter followed by a floxed stop cassette and a downstream TurboGFP with the
172 goal to only allow for TurboGFP expression after the excision of the stop cassette by
173 Cre (**Figure 1B**). Using CRISPR/Cas9 genome editing, we first targeted the MYL2-
174 tdTomato construct into two hiPSC lines derived from healthy donor patients (**Figure**
175 **1B**). Using an inside-out PCR strategy (Galdos et al., 2021; Ran et al., 2013), we
176 confirmed the successful integration of the MYL2 construct based on the integration of
177 the 5' and 3' ends of the construct and selected a heterozygous integrated clone
178 (**Figure 1C**). We subsequently integrated the CMV-Lox-STOP-Lox-TurboGFP construct
179 into the CCR5 safe harbor site and confirmed successful integration via inside-out PCR
180 (**Figure 1C**). Next, we integrated the P2A-Cre-P2A-Cre construct into the *TBX5* locus
181 by replacing the stop codon of the gene. To ensure maximal sensitivity of our lineage
182 tracing system, we integrated the *P2A-Cre* construct in a homozygous manner to
183 ensure high expression of Cre recombinase upon expression of *TBX5* (**Figure 1C**).
184 Importantly, the expression of *TBX5* is preserved with this approach since the Cre
185 recombinase is inserted after the *TBX5* coding sequence and the fusion protein product
186 undergoes self-cleaving at the P2A sequence (Liu et al., 2017). Using sanger
187 sequencing, we validated the in-frame integration of the P2A sequences of both the
188 *MYL2* and *TBX5* constructs (**Figure 1D**). Lastly, we confirmed the maintenance of
189 pluripotency after three rounds of genome editing by immunostaining of pluripotency
190 marker *OCT4*, *NANOG*, and *TRA-1-8-1* (**Figure 1E**), thus demonstrating the successful
191 genome editing of three independent genetic constructs into two different hiPSC lines.
192

193 **TBX5-Lineage/MYL2 Reporter System Reveals Predominance of Left Ventricular**
194 **Differentiation Using Small Molecule Wnt Protocol**
195

196 To determine the proportion of hiPSC-derived cardiomyocytes that exhibit a
197 TBX5-lineage positive phenotype, we conducted cardiac differentiations using a widely
198 published differentiation protocol consisting of biphasic activation and subsequent
199 inhibition of WNT signaling using small molecules (**Figure 1A, see Methods**) (Lian et
200 al., 2013). We employed a strategy where we conducted a high throughput flow
201 cytometry analysis of cardiac troponin, TurboGFP, and tdTomato expression across
202 multiple timepoints during cardiac differentiation and across the two independent cell
203 lines containing our reporter system (**Figure 2A, 2B, and 2C**). Analysis of *TNNT2*
204 expression from day 3 to day 30 of differentiation revealed a gradual upregulation of
205 *TNNT2* expression starting at day 7 of differentiation (**Figure 2B and 2D**), with the
206 greatest increase in *TNNT2*+ cardiomyocytes being reported between day 7 and 11 of
207 differentiation. Overall cardiac differentiation at day 30 across both reporter lines (WTC
208 and SCVI-111) averaged $93.2\% \pm 0.80\%$ and $92.1\% \pm 1.60\%$ of *TNNT2*+ cells out of total
209 cells analyzed, respectively (**Figure 2D**). We further analyzed the proportion of cells that
210 were positive for TurboGFP+ between day 3 and day 30 of differentiation (**Figure 2B**
211 **and 2E**) and found a large increase in TurboGFP+ cells between days 7 and 11 with a
212 continuous increase in the level of GFP signal as the differentiation proceeded. By day
213 30, both WTC and SCVI-111 lines exhibited $99.0\% \pm 0.21\%$ and $93.2\% \pm 0.84\%$ of total
214 *TNNT2*+ cardiomyocytes expressing TurboGFP, respectively, indicating a
215 predominance of cardiomyocytes from the TBX5 lineage (**Figure 2E**).

216 Since TBX5 is known to be expressed in both atrial and ventricular
217 cardiomyocytes, we next determined the percentage of ventricular cardiomyocytes that
218 are within the TBX5-lineage by analyzing the proportion of MYL2-tdTomato+
219 cardiomyocytes that express TurboGFP. *MYL2* expression gradually increases over
220 time during both hiPSC cardiac differentiation and *in vivo* development and is highly tied
221 to the overall maturational status of hiPSC-derived cardiomyocytes (Bizy et al., 2013;
222 Chirikian et al., 2021; DeLaughter et al., 2016; Li et al., 2016; O'Brien et al., 1993).
223 Consistent with previous studies, we show that the percentage of MYL2-tdTomato+
224 cardiomyocytes increases between days 15 and 30 of cardiomyocyte differentiation with
225 some line-to-line variability likely tied to variation in hiPSC-CM maturation rate thus
226 accounting for the higher percentage seen in the WTC line over the SCVI-111 (**Figure**
227 **2C and 2F**). Across day 15, 20, and 30 we observed that for both cell lines the
228 proportion of ventricular cardiomyocytes marked by the tdTomato reporter were more
229 than 95% for TurboGFP indicating that nearly all ventricular cardiomyocytes were within
230 the TBX5-lineage (**Figure 2F**, **Figure 2G**, **Figure 3A**).

231 We further validated the expression kinetics of our reporter system by conducting
232 bulk gene expression analyses using RT-qPCR across multiple timepoints during hiPSC
233 differentiation (**Figure 3B-3E**). We evaluated the expression of known markers of early
234 FHF progenitors and left ventricular cardiomyocytes, *HAND1* and *TBX5* (Barnes et al.,
235 2010; de Soysa et al., 2019; Devine et al., 2014; Vincentz et al., 2017). We also
236 evaluated the expression of Cre recombinase throughout differentiation. Relative to day
237 0 we observed that all three markers exhibited high expression values with *HAND1*
238 exhibiting more than 50,000 fold upregulation relative to day 0 by day 7 of differentiation

239 across both lines (**Figure 3B**). Similarly, by day 30 of differentiation *TBX5* exhibited
240 nearly 3,000-fold upregulation relative to day 0 (**Figure 3B**). The expression of Cre
241 recombinase increased over time and was consistent with the expected increase in
242 TurboGFP expression observed in the flow cytometry data (**Figure 3B**).

243 In addition to analyzing FHF marker expression, we also examined the
244 expression of SHF markers such as *ISL1*, *FGF8*, and *TBX1* (**Figure 3C**) (Cai et al.,
245 2003; Park et al., 2008; Rana et al., 2014). While *ISL1* has been reported to be
246 expressed in the early FHF lineage (Ma et al., 2008), a well-established observation is
247 that *ISL1* expression is sustained during the emergence of the SHF (Cai et al., 2003).
248 Interestingly, we observed in both the WTC and SCVI-111 that *ISL1* expression peaked
249 at day 5 of differentiation, which is indicative of an early cardiac progenitor population at
250 that timepoint. We did not observe a sustained expression of *ISL1* and rather observed
251 its downregulation over time. Similarly, *FGF8* has been reported to be important for
252 early cardiomyocyte differentiation in both the FHF and SHF, however, its expression is
253 maintained within SHF progenitors during cardiogenesis. We observed that while *FGF8*
254 expression was present at the mesodermal stage of differentiation (**Figure 3C**), a
255 significant drop in expression was observed after day 7. *TBX1*, a pharyngeal endoderm
256 and mesoderm marker (Chapman et al., 1996; Mesbah et al., 2012; Rana et al., 2014;
257 Vitelli et al., 2002), also known as marker of the anterior second heart field (Liao et al.,
258 2008; Meilhac and Buckingham, 2018; Nevis et al., 2013), was unexpectedly
259 upregulated during gastrulation and early cardiac progenitor stages of differentiation but
260 declined after day 7 of differentiation with some line-to-line and batch-to-batch variability
261 (**Figure 3C**). Importantly, *TBX1* was not upregulated to the same degree as either

262 *HAND1* or *TBX5*, both of which exhibited greater than 1000-fold upregulation in both
263 lines analyzed. This lack of SHF markers upregulation after day 7 contrasts with the
264 continued or even increased expression of FHF markers *HAND1* and *TBX5*, thus
265 indicating the predominance of FHF-derived cells at later stages of differentiation.
266 Notably, the fold change expression of *TBX1* and *ISL1* were significant lower than that
267 of *HAND1* and *TBX5*, with the FHF markers exhibiting more than 100,000- and 1000-
268 fold increase, respectively (**Figure 2B and 2C**). Lastly, we also observed an increase in
269 cardiomyocyte maturation markers such as *TNNT2*, *MYL2*, and *MYH7* (**Figure 3E**)
270 indicating the reporter lines fully differentiated into beating cardiomyocytes (**Video 1**
271 **and 2**). Consistent with our flow cytometry data, we also observe a gradual upregulation
272 of *MYL2* through the course of hiPSC cardiac differentiation. (**Figure 2B and 2E**).
273

274 **scRNA-seq Time Course Reveals Three Major Developmental Trajectories During**
275 **hiPSC Differentiation**
276

277 Given that our Cre/LoxP-based fluorescent reporter system showed a
278 predominance of *TBX5*-lineage cardiomyocytes (**Figure 2E**) and our qPCR data
279 showed an upregulation of FHF, but not SHF, gene markers at late stages of
280 differentiation (**Figure 3B and 3C**), we asked whether scRNA-seq may help to pinpoint
281 the developmental trajectories that bifurcates between FHF and SHF during hiPSC
282 differentiation. Using sample multiplexing with CMO in our scRNA-seq experiment
283 where we captured cells from both the WTC and SCVI-111 lines and at 12 different
284 timepoints hiPSC cardiac differentiation (Days 0 to 7 and 11, 13, 15, and 30) for a total

285 of 27,595 cells after sample demultiplexing and quality control (**Figure 4A, Figure 4-**
286 **figure supplement 1, 2, and 3**).

287 Using a well published batch correction method known as the mutual nearest
288 neighbor algorithm (Haghverdi et al., 2018), we batch corrected the effect of the scRNA-
289 seq runs and conducted downstream dimensionality reduction and unsupervised
290 clustering (**Figure 4-figure supplement 4**). Annotation of unsupervised clusters
291 revealed 13 major populations during cardiac differentiation (**Figure 4 and Figure 4-**
292 **figure supplement 4, Figure 4-Source Data 2**). During the early days of differentiation
293 we identified cell populations consistent with pluripotent stem cells, primitive streak, and
294 definitive endoderm populations marked by the expression of *POU5F1*, *MIXL1*, and
295 *SOX17*, respectively (**Figure 4-figure supplement 4, Figure 4-Source Data 2**) (Mead
296 et al., 1996; Pijuan-Sala et al., 2019; Takahashi and Yamanaka, 2006; Tyser et al.,
297 2021).. By day 3 of differentiation, we observed the emergence of mesodermal
298 progenitors, early cardiac progenitors, late cardiac progenitors, cardiomyocytes, and
299 epicardial populations marked by the expression of *MESP1*, *ISL1*, *NKX2-5*, *TNNT2*,
300 and *WT1*, respectively (**Figure 4-figure supplement 4, Figure 4-Source Data 2**)
301 (Barnes et al., 2010; Christoffels et al., 2009; Rudat and Kispert, 2012; Zeng et al.,
302 2011)..

303 Given the identification of distinct cell types within our single cell data, we asked
304 whether we could further identify developmental trajectories during hiPSC cardiac
305 differentiation. We used a Python based bioinformatic pipeline known as STREAM to
306 automatically identify and visualize differentiation trajectories within our scRNA-seq data
307 (Chen et al., 2019). STREAM uses a low dimensional manifold such as a UMAP plot

308 and calculates a principal graph that identifies differentiation paths throughout the
309 dataset. Intriguingly, the STREAM algorithm fit a principal graph that identified two
310 major bifurcations during hiPSC differentiation (**Figure 4D and Figure 4-figure**
311 **supplement 5**). Along with the fitting of a principal graph, we calculated STREAM
312 pseudotime by setting the pluripotent stem cell cluster as the root of the differentiation.
313 We then reordered and projected cells along the principal graph according to increasing
314 pseudotime to visualize our annotated cell types as they progressed during
315 differentiation (**Figure 4D-F and Figure 4-figure supplement 5**). To further
316 characterize the distinct trajectories identified by STREAM, we correlated the
317 expression of gene expression with the cell pseudotime along each unique branch
318 (**Figure 4-Source Data 3**). This analysis recovered multiple gene markers known to be
319 expressed during the course gastrulation and cardiac development. The first bifurcation
320 identified occurred at the late primitive streak stage and represents the bifurcation into
321 mesodermal and endodermal cell lineages. Gene markers identified for the endodermal
322 lineage includes markers such as *EPCAM* and *FOXA2*, as well as hepatic-like
323 endodermal markers such as *APOA1* and *AFP* (**Figure 4G**) (Hurrell et al., 2019; Pijuan-
324 Sala et al., 2019; Sarrach et al., 2018). Along the mesodermal differentiation path, we
325 observed the upregulation of *MESP1* followed by *ISL1* expression as cells became
326 specified along the cardiac progenitor lineage. *ISL1* expression preceded the
327 expression of *NKX2-5* and encompasses both endodermal precursors as well as
328 cardiac progenitors, supporting the earlier but less cardiac specific expression of *ISL1*.
329 At the second bifurcation, we identified an *NKX2-5* population that bifurcated into
330 myocardial and epicardial lineages. Top ranking markers for the epicardial lineage

331 included known epicardial marker *TBX18*, *WT1*, *TCF21*, and *IGF2*, while the myocardial
332 lineage was characterized by the elevated expression of sarcomeric genes (**Figure 4G**
333 **and Figure 4-figure supplement 5D**) (Christoffels et al., 2009; Hu et al., 2020; Li et al.,
334 2011; Rudat and Kispert, 2012; Tandon et al., 2013). Within the epicardial lineage, we
335 observed a high expression of *HAND1* along with the enrichment of extracellular matrix
336 genes such as *COL3A1*, *VIM*, and *COL1A1* at the epicardial progenitor population,
337 suggesting the emergence of *WT1* positive epicardial cells from a *HAND1* expressing
338 precursor (**Figure 4-Source Data 3**). Together, STREAM revealed the emergence of
339 an epicardial and myocardial lineage from a common cardiac progenitor during hiPSC
340 differentiation.

341
342 **Predominance of FHF Cardiomyocyte Differentiation by hiPSCs Confirmed by**
343 **Comparison with scRNA-seq Data from Murine Heart Field Development**

344
345 To confirm the FHF cardiomyocyte-predominant differentiation of hiPSCs that we
346 observed in our *TBX5* lineage tracing (**Figure 2D**) and qPCR (**Figure 3B, 3C**) data, we
347 conducted a comparison between previously published murine scRNA-seq heart field
348 data (de Soysa et al., 2019; Hill et al., 2019; Pijuan-Sala et al., 2019) and our hiPSC
349 cardiac differentiation data. We clustered data from the murine datasets representing 7
350 major cell types of interest including nascent mesoderm, heart field progenitors,
351 epicardial cells, left and right ventricular cardiomyocytes, and outflow tract
352 cardiomyocytes (**Figure 5A**). As previously reported (de Soysa et al., 2019; Hill et al.,
353 2019), we observed a bifurcation of the FHF and SHF cells from the nascent mesoderm
354 and observed a clear contribution of both heart field progenitors to the development of
355 left and right ventricular cardiomyocytes with FHF cells contributing to the LV and SHF

356 cells contributing to the RV/OFT. Intriguingly, we observed the epicardial lineage
357 branched off from FHF progenitor cells (**Figure 5B**). This observation is consistent with
358 the recent lineage tracing literature that indicates the contribution of a subset of FHF
359 progenitors to both left ventricular cardiomyocytes as well as epicardial cells (Tyser et
360 al., 2020; Zhang et al., 2021).

361 To further dissect the gene expression changes that occur during FHF and SHF
362 development, we replotted each FHF and SHF cell population using STREAM and
363 displayed the expression of known FHF and SHF progenitors markers during murine
364 heart field development and hiPSC cardiac differentiation (**Figure 5B**). Consistent with
365 the literature, *Tbx5* and *Hcn4* were upregulated in FHF cells during mouse development
366 in vivo and are completely absent in the aSHF lineage (**Figure 5C**) (Andersen et al.,
367 2018; Bruneau et al., 2001; Devine et al., 2014; Später et al., 2013). Of note, *Tbx5*
368 appeared to gradually increase in expression during the transition from FHF progenitors
369 to LV CMs with a gradual downregulation as development progresses, indicating a
370 dynamic expression pattern through the course of development. In contrast to the FHF
371 markers, we observed a clear upregulation of aSHF markers *Tbx1* and *Fgf8* during early
372 aSHF progenitor development in mice with *Fgf8* exhibiting its highest expression pattern
373 at prior to the bifurcation between OFT CM and RV CM (**Figure 5C**) (Nevis et al., 2013;
374 Park et al., 2008; Vitelli et al., 2002). As expected, the expression of *Tbx1* and *Fgf8*
375 were absent in FHF progenitors, albeit a low *Fgf8* expression was found in early LV CM,
376 which is expected given the role of Fgf signaling during early cardiomyocyte
377 differentiation (Khosravi et al., 2021; Reifers et al., 2000). We next plotted the
378 expression of these markers during our hiPSC cardiac differentiations and observed a

379 striking consistency in marker expression with the FHF lineage in the mouse (**Figure**
380 **5D**). Importantly, we observed the upregulation of TBX5 starting at the late progenitor
381 stage and increasing during the myocardial branch of the differentiation, like the kinetics
382 observed in the FHF trajectory of the mouse (**Figure 5D**). Similarly, *HCN4* expression
383 remained high during cardiomyocyte differentiation further supporting the left ventricular
384 identity of the myocardial branch given reported role of *HCN4* as an early FHF and LV
385 marker (Später et al., 2013).

386 Having observed the similarities between murine FHF development and our
387 hiPSC differentiations, we asked whether our hiPSC differentiations exhibited a
388 ventricular specific differentiation trajectory. We confirmed the ventricular specific
389 trajectory of our hiPSC differentiation given the gradual upregulation of the ventricular
390 specific Iroquois transcription factor, *IRX4* (**Figure 5E**) (Nelson et al., 2016, 2014).
391 Previous studies have shown *IRX4* to mark early ventricular specific cardiomyocytes,
392 which we effectively observed in both the left and right ventricular differentiation
393 lineages in the murine data (Nelson et al., 2014). We further confirmed the ventricular
394 specific differentiation of our hiPSC-derived CMs by observing the absence of atrial
395 markers, *KCNA5*, *NR2F1*, and *VSNL1* (**Figure 4-figure supplement 7D**). Lastly,
396 consistent with the MYL2-tdtomato expression pattern observed with our reporter lines
397 (**Figure 2F**), we observed the gradual upregulation of MYL2 in both the human and
398 murine datasets. Together, our analysis provides evidence for the predominance of FHF
399 ventricular cardiomyocyte development during hiPSC differentiation.

400

401 **Comparison of 2D and 3D Cardiac Differentiation Uncovers Potential of Organoid**
402 **System for SHF Generation**

403

404 Recently, multiple groups have proposed the use of 3D differentiation to better
405 model chamber morphogenesis and potentially model both first and second heart field
406 development *in vitro* (Andersen et al., 2018; Drakhlis et al., 2021; Protze et al., 2019b;
407 Rossi et al., 2021). Interestingly, murine gastruloid and precardiac organoids have been
408 shown to exhibit aspects of first and second heart field development (Andersen et al.,
409 2018; Rossi et al., 2021); however, data on the ability to generate both heart fields in
410 human iPSCs are lacking. Given the predominance of FHF progenitors and LV
411 cardiomyocytes made from our 2D hiPSC differentiation platform, we assessed
412 whether a greater repertoire of cardiac cells can be generated from a 3D hiPSC
413 differentiation platform by analyzing scRNA-seq data from a recently published cardiac
414 organoid study (Drakhlis et al., 2021). This paper demonstrated the close relationship
415 between anterior endoderm lineages and anterior second heart field cells during hiPSC
416 differentiation by showing that anterior foregut endoderm can be generated alongside
417 cardiac lineage cell types (Kelly et al., 2001; Rochais et al., 2009). We compared
418 scRNA-seq data from our hiPSC-derived cardiac cells with those generated by the
419 Drakhlis et al group using their 3D differentiation protocol (Drakhlis et al., 2021). We first
420 conducted a cross dataset comparison of FHF and SHF marker analysis where we
421 focused exclusively on cell types composing the myocardial lineages of both datasets
422 (**Figure 6A**). In our 2D cardiac differentiation we observed a clear increased expression
423 of FHF markers *TBX5*, *HCN4* and *HAND1* during differentiation with the absence of
424 SHF markers *FGF8* and *TBX1* (**Figure 6B and 6C**). Interestingly, the day 13 data from
425 Drakhlis et al showed two clusters exhibiting distinct transcriptional expression patterns

426 suggestive of FHF and SHF progenitors (**Figure 6D**), with both clusters appearing to
427 give rise to *TNNI1* and *NKX2-5* positive cardiomyocytes. Cluster 2 and 8 of the cardiac
428 organoid data indicated a high expression of *TBX5*, *HAND1*, along with the upregulation
429 *HCN4* during differentiation which was consistent with the FHF trajectory we observed
430 in our 2D data (**Figure 6E**). Interestingly, we found that cells in cluster 4, 7, 10 of
431 Drakhlis et al. exhibited a high expression of *TBX1*, *FGF8*, and *ISL1*, all of which were
432 consistent with a SHF identity (Cai et al., 2003; Mesbah et al., 2012; Park et al., 2008).
433 Moreover, we also observed a cardiomyocyte population emerging from the *TBX1*+

434 population that was negative for FHF markers *TBX5* and *HCN4*, but highly expressing
435 *ISL1* and *HAND1*, which is suggestive of an OFT CM population that is known to
436 express *HAND1* and emerge from *ISL1* expressing SHF progenitors.

437 To determine whether this *TBX5*-*ISL1*+-*HAND1*+ cardiomyocyte population was
438 indeed OFT CMs, we conducted a joint analysis of the cardiomyocytes from our 2D
439 differentiations and the Drakhlis et al. cardiac organoid. Using unsupervised clustering,
440 we observed a cardiomyocyte population emerge from this study that displayed the
441 absence of *TBX5*. Interestingly, we observed that the rest of the organoid
442 cardiomyocytes co-clustered with the cells from our 2D differentiations indicating shared
443 gene expression profiles (**Figure 6F**). We conducted differential gene expression
444 analysis of the putative OFT CM cluster and the rest cardiomyocytes and found a
445 statistically significant enrichment of markers associated with OFT development
446 including *HAND1*, *BMP2*, *WNT5A*, and *PITX2* (Délot et al., 2003; Li et al., 2016; Ma et
447 al., 2013; Schleiffarth et al., 2007), while the rest of the cardiomyocytes exhibited high
448 expression of markers associated with early LV development such as *TBX5* and *NPPA*

449 (Figure 6G, Figure 6-Source Data 1) (Li et al., 2016). Overall, these data thus provide
450 strong evidence for the emergence of a SHF derived cell type within a 3D organoid
451 differentiation protocol and reinforce the left ventricular identity that we identified using a
452 standard 2D small molecule differentiation protocol.

453

454 **DISCUSSION**

455 Over the past decade, the development of highly efficient cardiac directed
456 differentiation protocols have significantly advanced efforts to model cardiovascular
457 diseases *in vitro* (Burridge et al., 2015; Lian et al., 2013). While non-human model
458 systems have provided significant insight into the developmental lineages that
459 contribute to cardiac development, the inaccessibility of early human embryonic tissue
460 has significantly limited the creation of an *in vivo* reference atlas of human heart field
461 development. Importantly, questions remain as to whether the human iPSC system can
462 be used to efficiently generate cell types representing distinct chambers of the heart
463 such as left/right ventricular cardiomyocytes, outflow tract cardiomyocytes, or
464 atrioventricular canal cells. Currently, a major gap exists in the ability to model the
465 development of specific structures of the human heart in part due to the lack of genetic
466 tools to mark distinct cell lineage *in vitro*. Importantly, the ability to identify chamber
467 specific cardiomyocyte is vitally important to modeling the early developmental
468 mechanisms that give rise to structural congenital heart defects (Doyle et al., 2015;
469 Reller et al., 2008; van der Linde et al., 2011).

470 In this paper, we sought to build a novel genetic lineage tracing tool to elucidate
471 the identities of cardiomyocytes generated using a well cited and standard

472 differentiation protocol. We successfully implemented a *TBX5* lineage tracing scheme
473 into the hiPSC system by targeting a highly sensitive Cre recombinase to the 3' end of
474 the endogenous *TBX5* locus. Moreover, by including an *MYL2*-TdTomato direct
475 reporter into our hiPSC lines, we evaluated the percentage of ventricular
476 cardiomyocytes that were descended from *TBX5* expressing precursors. By
477 implementing a lineage tracing method, our reporter system provides several
478 advantages for studying the descendants of FHF progenitor cell types compared with
479 previous approaches. While previous studies have shown the isolation of *TBX5*-positive
480 cell types using direct reporter schemes (Zhang et al., 2019), a major advantage of a
481 lineage tracing approach is the permanent and robust labeling of descendants from
482 progenitor populations or cardiomyocyte populations that express *TBX5*, thus allowing
483 for the evaluation of cell type identity at later stages of differentiation when *TBX5*
484 expression is downregulated. Moreover, the combination of our lineage tracing and a
485 ventricular reporter system allowed us to evaluate the proportion of definitive ventricular
486 cardiomyocytes from the *TBX5*-lineage during iPSC differentiation that generates atrial
487 cardiomyocytes as well.

488 Surprisingly, our data indicates that in two distinct hiPSC lines, *TBX5*-lineage-
489 positive cardiomyocytes represent more than 95% of all cardiomyocytes generated.
490 Furthermore, our scRNA-seq time course data further revealed the emergence of a core
491 cardiac progenitor differentiation trajectory that displayed a gradual upregulation of FHF
492 markers and no expression of known SHF genes. The unexpected finding of FHF
493 predominance raises important questions on whether the widely used small molecule
494 WNT modulation protocol used for the generation of hiPSC cardiomyocytes is biased

495 towards the generation of FHF lineage cardiomyocytes. An additional finding from our
496 scRNA-seq analysis that was quite intriguing was the bifurcation of cardiac progenitors
497 into epicardial and myocardial cells. Importantly, the epicardial lineage arose from a cell
498 cluster that exhibited high expression of *HAND1* representing early FHF progenitor
499 cells. Recently, two groups have published lineage tracing results in mice that suggest
500 a subset of FHF progenitor cells exhibit contributions to both the proepicardial and
501 myocardial lineages (Tyser et al., 2020; Zhang et al., 2021). Consistent with these
502 studies, our data provides evidence of this bifurcation *in vitro* and demonstrates the high
503 expression of left ventricular markers *HAND1*, *TBX5*, and *HCN4* along the myocardial
504 lineage. The high expression of *HAND1* during the earliest stages of mesoderm
505 differentiation further suggests that even at the earliest stages of mesoderm
506 specification the progenitors in our hiPSC differentiations were already bound for a FHF
507 fate given the known restriction of *HAND1* to give rise to FHF derived cell types during
508 early embryonic development (Barnes et al., 2010; Vincentz et al., 2017). This
509 observation is consistent with a growing body of literature suggesting that the bifurcation
510 of first and second heart field occurs during the earliest patterning of mesoderm during
511 its emergence from the primitive streak (Lescroart et al., 2014).

512 Having established the FHF identity of our cardiac differentiation conducted in
513 2D, we used our dataset as a reference point for determining whether a recently
514 published cardiac organoid protocol could give rise to a greater diversity of cardiac
515 progenitor cell types. While multiple 3D protocols have recently been published, the
516 study by Drakhlis et al. is the only protocol to date to demonstrate the co-emergence of
517 anterior endoderm cell types that are closely related the emergence of an anterior cell

518 types such as the anterior second heart field during embryonic development.
519 Interestingly, our comparison revealed the presence of *bona fide* second heart field
520 progenitors within the organoids generated in the Drakhlis et al. protocol. Importantly,
521 we were able to combine cardiomyocytes generated from our study with those from the
522 Drakhlis et al 3D protocol and reveal the identity of a true OFT cell type present in the
523 Drakhlis et al dataset (**Figure 6F**). This analysis thus reveals the promising application
524 of 3D differentiation protocols for generating a greater diversity of cardiac cell types.

525 Overall, here we provide a novel reporter system that allows for the identification
526 of left ventricular cardiomyocytes during the course hiPSC differentiation. By allowing
527 for the permanent labeling of *TBX5* descended cell types, we envision our system being
528 used to conduct more complex studies to study chamber specific cardiomyocytes in the
529 context of congenital heart diseases as well as for the development of novel hiPSC
530 differentiation protocols for generating both left and right ventricular cardiomyocytes.
531 Moreover, by generating a scRNA-seq dataset profiling multiple consecutive day of
532 hiPSC cardiac differentiation we provide here reference atlas of the differentiation
533 events that occur during human *in vitro* cardiac development. Together, our study
534 provides extensive evidence of the identification of the FHF lineage in a human system
535 and reveals the early bifurcation of this lineage into an epicardial and myocardial
536 lineage.

537

538

539

540

541 **MATERIALS AND METHODS**

542 Cell Lines:

543 Human induced pluripotent stem cell lines used in this study were obtained from the
544 Stanford Cardiovascular Institute Biobank (SCVI-111, Sendai virus reprogrammed
545 peripheral blood mononuclear cells, healthy male with normal karyotype, 46, XY). The
546 WTC-11 (reprogrammed from healthy males with normal karyotype, 46, XY) hiPSC line
547 was provided by Bruce Conklin's laboratory at the University of California, San
548 Francisco and has been deposited into the Coriell Institute for Medical Research under
549 identifier GM25256. For SCVI-111, G-banding karyotyping was conducted and cell line
550 identity was confirmed by short tandem repeat analysis of the cell line and donor
551 PBMCs. For the WTC-11 line, G-banding karyotyping was conducted and cell line
552 identity was confirmed by short tandem repeat analysis of the cell line to donor
553 fibroblasts. All cell lines tested negative for mycoplasma. Studies involved human iPSCs
554 approved under protocol #460 of the Stanford Stem Cell Research Oversight (SCRO)
555 committee.

556

557 Cardiac Differentiation:

558 HiPSCs were maintained in DMEM/F12 (Corning Cat. 10-092-CM) supplemented with
559 essential eight (E8) (henceforth referred to as E8 media) that is prepared in-house as
560 previously described (Burridge et al., 2015) and cultured on growth factor reduced
561 Matrigel (Corning Cat. 356321) coated plates at a 1:300 dilution. Upon reaching 75-80%
562 confluence, hiPSCs were passaged using 0.5 mM EDTA in PBS for 8 minutes at 37°C.
563 Passaging was conducted with gentle dissociation of cell clusters and plated in E8

564 media supplemented 10 μ M ROCK inhibitor (Selleckchem Cat. S1049). Passaging was
565 performed using 1:12 splitting ratio to achieve approximately 10,000 cells per cm². 24
566 hours after passaging media was changed to E8 media. Daily media changes were
567 conducted until cells reached 90-95% confluence at which point media was change to
568 RPMI-1640 (Corning Cat. 10-040-CV) containing 6 μ M CHIR99021 (Selleckchem Cat.
569 CT99021) and 2% B27 minus insulin supplement (ThermoFisher Cat. A1895601). Two
570 days after initial treatment with CHIR, media was changed to RPMI-1640 with 2% B27
571 minus insulin for 24 hrs. Between day 3-5, media was changed to 2 μ M C59
572 (Selleckchem Cat. S7037) in RPMI-1640 media with 2% B27 minus insulin. On day 5 of
573 differentiation, media was changed for RPMI-1640 with 2% B27 minus insulin for 48 hrs
574 and was subsequently changed to RPMI-1640 with 2% B27 Plus Insulin (ThermoFisher
575 Cat. 17504044) for another 48 hrs. On day 9, cells underwent glucose deprivation for 48
576 hrs to purify cardiomyocytes by changing media to RPMI-1640 minus glucose with 2%
577 B27 Plus insulin. Cardiomyocytes were subsequently maintained in RPMI-1640 with
578 glucose with 2% B27 Plus Insulin.

579

580 Donor Construct Plasmids

581 Cre recombinase gene sequence was provided by Connie Cepko lab (Addgene plasmid
582 # 13775) (Matsuda and Cepko, 2007). TurboGFP gene was obtained from the
583 pMaxGFP plasmid obtained from the Lonza P3 Primary Cell 4D-Nucleofector X Kit L.
584 Plasmids were constructed using plasmid construct service by Genscript Biotech. All
585 donor plasmids are freely available upon request.

586

587 **CRISPR/Cas9 Genome Editing:**

588 Genetic constructs were targeted to hiPSCs following the schematic presented in Figure

589 1. TurboGFP sequence was cloned from the pMaxGFP plasmid from Lonza P3 Primary

590 Cell Nucleofection kit. Protocol for targeting of genetic constructs was followed as

591 previously described (Galdos et al., 2021). Briefly, hiPSCs were dissociated into a

592 single cell suspension at 75% confluence using an Accutase-EDTA solution (Millipore

593 Cat. SCR005) containing a 0.02% blebbistatin (Sigma-Aldrich Cat. B0560). Dissociation

594 reaction was quenched using a solution of E8 media with 10 μ M ROCK inhibitor and

595 0.02% blebbistatin. Cells were then pelleted by centrifugation at 200g for 3 minutes.

596 We subsequently conducted nucleofection of the dissociated cells using the Lonza P3

597 Primary Cell 4D-Nucleofector X Kit L. A transfection mix was prepared containing the

598 Lonza P3 Solution, Supplement, single guide RNA/Cas9 expressing plasmid (1 μ g), and

599 the donor template plasmid (3 μ g). Single Guide RNA sequences are found in **Figure 1-**

600 **Source Data 2.** Cells were electroporated using a Lonza 4D Nucleofector machine

601 using protocol number “CM150”. After electroporation, 1 mL of E8 media supplemented

602 with 10 μ M ROCK inhibitor was gently added to the cuvette containing the cells. Cells

603 were allowed to rest for 10 minutes after which they were plated onto two wells of a 6

604 well plate. 24 hrs after plating, media was changed to regular E8 media, and regular

605 maintenance until cells reach 50% confluence. At the 50% confluence mark, cells were

606 dissociated into single cell suspensions and passaged onto 6 well plates at 1000 cells

607 per well of 6-well. We subsequently maintained the transfected hiPSCs in E8 media

608 supplemented with appropriate antibiotic for selection of successfully targeted cells.

609 Concentrations were as follows for the constructs targeted: TBX5-Cre (Hygromycin 150

610 µg/mL ThermoFisher Cat. 10687010), CCR5-CLSL-TurboGFP (G418 150 µg/mL Sigma
611 Cat. 4727878001), and MYL2-Tdtomato (Puromycin 0.2 µg/mL Sigma Cat. P8833).
612 After 5 days of treatment with antibiotic, cells were switched to regular E8 to allow for
613 colony expansion derived from single cells plated. After 4 days of colony expansion,
614 colonies were picked into 24-well plates containing E8 plus 10 µM ROCK inhibitor and
615 were expanded for downstream DNA extraction using Qiagen DNeasy Kit and for cell
616 freezing using Bambanker.

617 PCR validation of construct integration was conducted using the “Inside-Outside”
618 approach where one primer was designed outside of the homology arms of the donor
619 template and one primer was designed insight of the construct to be integrated. PCRs
620 were conducted using the GoTaq Master Mix (Promega Corporation Cat. M7122), and
621 products were run on a 1% agarose gel in 1X TAE Buffer. PCR primer sequences are
622 found in **Figure 1-Source Data 3.**

623

624 Immunofluorescence Staining

625 Immunocytochemistry was carried out for hiPSCs after genome editing and
626 clonal selection for pluripotency marker OCT4 (ThermoFisher Cat. MA1-104), Nanog
627 (ThermoFisher Cat. MA1-017), and Tra-1-8-1 (Stem Cell Technologies Cat. Tra-1-81).
628 Cells were fixed in 4% Paraformaldehyde solution in PBS for 15 minutes. Cells were
629 subsequently, washed three times for 5 minutes in 1X PBS. The PBS was gently
630 aspirated from cells and cells were incubated in a blocking solution composed of 1%
631 Bovine Serum Albumin (Sigma Cat. A7906), 0.1% Triton-X100 (Sigma Cat. T8787) in
632 PBS, and 1% Goat serum (Sigma Cat. 9023), for 1 hour at room temperature. After

633 blocking, mouse anti-OCT4 (2 µg/mL), mouse anti-Nanog (1:100 dilution), or mouse
634 anti-Tra-1-8-1 (5 µg/mL) antibody were diluted in blocking solution. Cells were incubated
635 in primary antibody solution overnight at 4 degrees Celsius. The next day, primary
636 antibody was aspirated, and cells were washed three times in wash buffer (0.1%
637 Tween-20 in PBS) for 5 minutes each. Cells were then rinsed in 1X PBS and then
638 incubated in secondary antibody solution consisting of Goat anti-mouse Alexa Fluor 647
639 (ThermoFisher Cat. A32728) secondary antibody at a 1:500 dilution and NucBlue DAPI
640 (ThermoFisher Cat. R37606) stain in blocking solution for one hour at room temperature
641 and protected from light. Next, secondary antibody solution was aspirated and cells
642 were washed three times in wash buffer and rinsed once in 1X PBS. Finally, chamber
643 slide cover slips were mounted using Diamond Anti-Fade mounting (ThermoFisher Cat.
644 P36961) media and were subsequently imaged.

645 For cardiac troponin (cTnT) staining, we followed the same staining protocol as
646 described above for pluripotency markers, however, we used mouse anti-cardiac
647 troponin T antibody (ThermoFisher Cat. MA5-12960) at a 1:300 dilution during the
648 primary antibody incubation. Goat anti-mouse Alexa Fluor 647 (ThermoFisher Cat.
649 A32728) antibody was used at a 1:500 dilution along with a NucBlue DAPI counterstain.
650

651 Flow Cytometry:

652 A Beckman Coulter CytoFLEX flow cytometer was used for high throughput analysis of
653 TNNT2, TurboGFP, and TdTomato expression across time of hiPSC cardiac
654 differentiation. On day of timepoint collection, cells were dissociated into single cell
655 suspensions by incubating in 10X TrypLE Select (ThermoFisher Cat. A1217701) for 5

656 minutes at 37 degrees Celsius. For later stage cardiomyocytes (day 15 and onwards)
657 incubation time was extended to 10 minutes to achieve single cell dissociation. Cells
658 were subsequently pelleted by centrifugation at 200g for 5 minutes. Cell pellets were
659 resuspended in 4% PFA for 10 minutes and were rinsed with a 5% KnockOut Serum
660 Replacement (ThermoFisher Cat. 10828028) solution in 1x PBS. Cells were
661 permeabilized in a 0.5% Saponin (Sigma Cat. S7900) solution containing 5% FBS in 1X
662 PBS (hereafter referred to as Saponin Solution). After permeabilization cells were
663 incubated for 45 minutes in a monoclonal mouse anti-Troponin primary antibody
664 (ThermoFisher Cat. MA5-12960) at a 1:200 dilution in 0.5% saponin solution. Cells were
665 rinsed twice in saponin solution and then incubated in secondary antibody AlexaFluor
666 647 goat anti-mouse (ThermoFisher Cat. A32728) at a 1:1000 dilution in 0.5% saponin
667 solution. Cells were subsequently rinsed in 1x PBS twice and analyzed using CytoFLEX
668 flow cytometer.

669
670 For sorting of TurboGFP+ and TurboGFP- day 15 cardiomyocytes, independent
671 biological replicates consisting of independent differentiations were sorted using a
672 FACSaria Fusion. Cells were dissociated using TRYPLE Select (ThermoFisher Cat.
673 A1217701) incubation by 5 minutes to ensure cells were fully dissociated. After single
674 cell suspensions were obtained, TRYPLE Select was neutralized with an equal volume
675 of replating media consisting of 10% Knockout Serum Replacement, 2% B27 Plus
676 Insulin Supplement, and RPMI-1640 with glucose. Cells were centrifuged at 200g for 5
677 minutes and pellets resuspended in 1 mL of replating media. Sorting was done into 10
678 mL falcon tubes containing replating media. After sorting, cells were centrifuged at 200g

679 for 5 minutes and lysed for RNA collection using Trizol Reagent (ThermoFisher Cat.
680 15596026). RNA extraction was done using the Zymo DIRECT-Zol extraction kit (Zymo
681 Research Cat. R2052) per manufacturer's protocol. Quantitative RT-PCR was done as
682 described below.

683
684 **RNA Extraction and Quantitative RT-PCR**
685
686
687 Cells were collected for RNA extraction by dissociation with 10X TrypLE Select and
688 pelleted as described in the Flow Cytometry section. Cell pellets were then
689 resuspended in 300 μ L of TRIZOL reagent (ThermoFisher Cat. 15596018) at room
690 temperature for 3 minutes. After complete resuspension of the cells, RNA was extracted
691 using the Zymo DIRECT-Zol extraction kit (Zymo Research Cat. R2052) per
692 manufacturer's protocol. Purified RNA was reverse transcribed into cDNA using the
693 High-Capacity RNA-to-cDNA kit (ThermoFisher Cat. 4387406). Quantitative PCR was
694 subsequently run on a Biorad qPCR 384-well machine using the Biorad SYBR qPCR
695 master mix. RT-qPCR primer sequences are found in **Figure 3-Source Data 1**.

696
697 **Sample Preparation for Multiplexed Single Cell RNA Sequencing**
698 To prepare cells for single cell RNA sequencing, we dissociated cells at desired
699 timepoints by incubating in 10X TRYPLE Select for 5 minutes at 37 degrees Celsius.
700 Cells were gently dissociated by repeated pipetting. For later timepoints (Days 15 and
701 30), we extended the TRYPLE Select (ThermoFisher Cat. A1217701) incubation by 5
702 minutes to ensure cells were fully dissociated. After single cell suspensions were
703 obtained, TRYPLE Select was neutralized with an equal volume of replating media

704 consisting of 10% Knockout Serum Replacement, 2% B27 Plus Insulin Supplement, and
705 RPMI-1640 with glucose. Cells were centrifuged at 200g for 5 minutes to obtain cell
706 pellets. For days 0 to 6 we resuspended cells in BamBanker freezing medium (GC
707 LTER Cat. 302-14681) and control rate freezed vials of cells at each timepoint collected
708 to obtain 2 million cells per freezing vial. For days 7 onwards we froze down cells in a
709 cardiomyocyte freezing medium consisting of 90% Knockout Serum Replacement and
710 10% cell culture grade DMSO (Sigma Cat. D2650).

711 For running the scRNA-seq experiment, we thawed the desired timepoints for
712 each experimental run by thawing vials of cell at 37 degrees Celsius and adding
713 replating media dropwise to each vial. Cells were then centrifuged at 200g for 5 minutes
714 to obtain cell pellets. We conducted two washes in sterile 1X DPBS for each sample to
715 wash away any remaining Knockout Serum that could interfere with the chemically
716 modified-oligonucleotide (CMO) staining. Using the 10X Genomics CellPlex kit, we
717 added 100 μ L of CMO to each cell pellet and resuspended the cells to allow the lipid
718 conjugated oligonucleotides to bind to each of our samples. Each CellPlex CMO
719 consists of a unique barcode that is used for identifying individual samples that are run
720 within a single channel of a 10X Genomics chip. After incubating for 5 minutes, 1000 μ L
721 of sterile 1X DPBS was added to each sample, and all samples were centrifuged for 5
722 minutes as 200g. Cells were transferred to 5 mL eppendorfs which allowed for two more
723 1x DPBS washes with a total of 5 mL DPBS for each sample. Washing of unbound
724 CMO was critical to ensuring minimal cross contamination of CMOs when combining
725 samples. After washing, we proceeded to follow the 10X Genomics 3' 3.1 with CellPlex
726 protocol for cell capture and combined samples as listed in **Figure 4-Source Data 4**.

727 We aimed to capture a total of 30,000 cells per well of a 10X Genomics GEM Chip.
728 After cell capture, we proceeded with preparing gene expression libraries and CellPlex
729 libraries by following 10X Genomic manufacturer's protocol. Libraries were sequenced
730 using an Illumina NovaSeq 6000 with S4 v1.5 flowcell reagents. We sequenced the
731 gene expression libraries at a depth of 25,000 paired-end reads per cell and the
732 CellPlex libraries at 5,000 paired-end reads per cell. Base calling during sequencing
733 was performed using Real Time Analysis Version 3 software.

734

735 Bioinformatic Analysis of HiPSC scRNA-seq Time Course

736 Raw FASTQ files were obtained for gene expression and CellPlex libraries and
737 were aligned using CellRanger-6.0.0 using the count function. We aligned the gene
738 expression libraries to prebuilt GRCh38 Human genome reference provided by 10X
739 Genomics at: <https://support.10xgenomics.com/single-cell-gene-expression/software/downloads/latest>. We aligned the CellPlex libraries using a list of
740 CMO barcodes as a reference as found in **Figure 4-Source Data 4**. After alignment, we
741 obtained gene by cell expression matrices containing individual counts for each gene
742 detected for each individual cell captured. We also obtained matrices containing the
743 counts for each CMO detected per cell.

745 Gene expression matrices for each single cell run were corrected for ambient
746 RNA contamination using the SoupX package v1.5.2 (Young and Behjati, 2020), which
747 detects levels of ambient RNA contamination using empty droplets processed during
748 the single cell capture. Following ambient RNA correction, we then imported the CMO
749 expression matrix into the Seurat R package version 4.1.0 and conducted log-ratio

750 normalization using the NormalizeData function. To demultiplex each sample according
751 to the CMO used for labeling, we ran the HTODemux function using default parameters.
752 This function assigns cell labels according to the amount of CMO counts detected per
753 cell. It also identifies cells that can be classified as singlets, doublets, or negative (did
754 not stain for any of the CMO labels).

755 After sample demultiplexing, we removed doublet and negative cells from the
756 dataset as part of our quality control pipeline. We then calculated the percent of all RNA
757 counts belonging to ribosomal and mitochondrial genes. To further remove low quality,
758 dead, or doublet cells, we calculated the median percentage of mitochondrial and
759 ribosomal RNA counts detected as well as the total RNA counts per cell and genes
760 detected per cell. We calculated an upper and lower cutoff for elimination of low-quality
761 cells by calculating the threshold at three times the median absolute deviation above
762 and below the median value of each of these quality control metrics. Cells above and
763 below these cutoffs were eliminated and the cells passing quality control were used for
764 subsequent analyses.

765 After quality control analyses, we proceeded to merge data from all three single
766 cell runs conducted. We normalized RNA counts per cell using the NormalizeData
767 function in Seurat and using default parameters. We then proceeded to integrate the
768 three single cell runs by using mutual nearest neighbor batch correction algorithm and
769 using the individual as the batch correction variable (Haghverdi et al., 2018). This was
770 done in order to correct for the technical variation that occurs from running single cell
771 samples in individual capture runs. To conduct the batch correction, we first identified a
772 common set of integration features across the three runs integrated by running the

773 SelectIntegrationFeatures function in Seurat. After identifying highly variable features
774 commonly found between the datasets, we further filtered these features by removing
775 features associated with cell cycle in order to remove the effect of cell cycle from
776 downstream analyses and clustering. We then ran the RunFastMNN function from the
777 SeuratWrappers version 0.3.0 package. After integration we then proceeded with
778 constructing the nearest neighbors graph by using the FindNeighbors function and used
779 15 principal components that were identified using the ElbowPlot method in Seurat. We
780 then proceeded to conduct non-linear dimensionality reduction by running the
781 RunUMAP function using 15 principal components. Lastly, we conducted unsupervised
782 clustering using the FindClusters function. We then conducted differential gene
783 expression analysis to annotate clusters based on literature reported cell markers.

784

785 Lineage Trajectory Analysis Using STREAM

786 To conduct lineage trajectory analysis of hiPSC cardiac differentiations, we
787 imported our integrated Seurat object into an AnnData object using ScanPy v1.8.2
788 package in Python (Wolf et al., 2018). After obtaining an AnnData object, we then fit a
789 principal graph to the UMAP plot calculated using Seurat using the
790 seed_elastic_principal_graph and elastic_principal_graph functions in STREAM version
791 1.1. In addition to fitting the principal graphs, we also calculated STREAM pseudotime
792 and ordered cells along this pseudotime using the principal graph calculation functions.
793 After calculating pseudotime, we projected cells across distinct differentiation
794 trajectories using the plot_flat_tree function and also plotted cells in a subway plot using
795 plot_stream_sc. These functions allowed for the visualization of cellular differentiation

796 along distinct differentiation paths identified by the STREAM algorithm and for
797 downstream identification of gene markers that are expressed during each trajectory
798 identified. After obtaining distinct differentiation trajectory branches across pseudotime,
799 we calculated the top differentially expressed genes across each major branch identified
800 by STREAM by using the detect_transition_markers function.

801

802 Comparison of hiPSC and Murine Cardiac Development scRNA-seq

803 To compare our hiPSC differentiation scRNA-seq data with murine data, we
804 downloaded data from GEO database from three previously published datasets. We
805 extracted cells of interest from these datasets representing nascent mesoderm, heart
806 field progenitors, left and right ventricular cardiomyocytes, outflow tract cardiomyocytes,
807 and epicardial cells. In order to jointly plot these cells across multiple different datasets,
808 we used the Fast Mutual Nearest Neighbor algorithm and integrated
809 the cells for each dataset together. We then proceeded to construct the shared nearest
810 neighbor graph and conduct dimensionality reduction using the RunUMAP function by
811 using the corrected principal components derived using the FastMNN algorithm.

812 To analyze the development of FHF and aSHF differentiation lineages,
813 respectively, we subsetted cells that are known from literature to fall along each lineage.
814 For example, for the FHF differentiation trajectory, we reclustered cells identified as
815 FHF Progenitors, epicardial cells, and left ventricular cardiomyocytes. For the anterior
816 second heart field, we clustered SHF progenitors along with right ventricular and outflow
817 tract cardiomyocytes. After subsetting the cells, we reran the FastMNN algorithm to
818 recalculate the corrected PCA space for the subsetted cells and continued with deriving

819 UMAP plots. These plots were then used to calculate principal graphs using STREAM
820 and to identify the differentiation lineages that arise during the progenitor's
821 differentiation trajectories. STREAM then allowed for the plotting of STREAM plots
822 along the differentiation trajectories identified, where we probed for the expression of
823 well-established FHF and aSHF genes. These genes were also evaluated using the
824 human iPSC cardiac differentiations using STREAM plots.

825

826 scRNA-seq Comparison of 2D and previously published 3D hiPSC Cardiac
827 Differentiation

828 To compare our 2D hiPSC cardiac differentiations to a previously published
829 cardiac organoid protocol, we downloaded data from Drakhlis et al from GSE150202
830 and subsetted the dataset for putative cardiomyocytes and cardiac progenitors. The
831 Drakhlis et al dataset was generated from two individual heart forming organoids,
832 therefore, to correct for the batch effect from these two independent organoids, we ran
833 the FastMNN algorithm to conduct dimensionality reduction using the FindNeighbors
834 and RunUMAP functions of Seurat. Moreover, we conducted unsupervised clustering of
835 the Drakhlis et al dataset where we identified major clusters of cardiac progenitors and
836 cardiomyocytes. To compare between our hiPSC 2D data and the Drakhlis et al data,
837 we plotted the expression of multiple FHF and SHF markers using features plots.
838 Moreover, we focused on the myocardial lineage on our hiPSC 2D differentiations to
839 conduct a direct comparison of the cardiomyocyte differentiation lineages in the
840 datasets.

841 To conduct unsupervised clustering of both the Drakhlis et al cardiomyocytes and
842 those from our 2D differentiations, we merged only the cardiomyocytes from the
843 datasets and batch corrected using FastMNN. We subsequently conducted
844 dimensionality reduction using FindNeighbors and RunUMAP in Seurat and conducted
845 unsupervised clustering of the cardiomyocyte populations. We then conducted
846 differential gene expression analysis by using the FindMarkers function in Seurat and
847 compared the expression of the putative outflow tract cluster with the rest of the
848 cardiomyocyte clusters. We then plotted a volcano plot using the EnhancedVolcano
849 package which allowed for the visualization of statistically significant upregulated and
850 downregulated markers in the OFT cluster relative to the other cardiomyocyte
851 populations. Adjusted P-values for the differential expression analysis were calculated
852 using Bonferroni correction for multiple comparisons.

853

854 Statistics:

855 For studies conducted in this manuscript, biological replicates were defined as
856 independently conducted differentiations where hiPSCs were independently plated and
857 carried through our standard differentiation protocol. Samples were collected at distinct
858 timepoints for the respective experiment. For quantitative PCR data, for each biological
859 replicate, we ran each gene for each timepoint in technical duplicates and the average
860 cycle threshold value for each technical replicates was taken for downstream analysis
861 using the delta-delta-Ct method.

862 Data presented in bar graphs for flow cytometry and RT-qPCR are presented as
863 a mean \pm standard error of the mean. Two-way ANOVA was conducted for statistical

864 analysis of flow cytometry data with first independent variable analyzed being time and
865 second variable being cell line. One way ANOVA with Dunnet's multiple comparisons
866 correction was conducted for statistical analysis of RT-qPCR data. For flow cytometry
867 data, outliers were removed based on percentage of cardiac troponin expressing cells
868 using the ROUT method for outlier detection (Motulsky and Brown, 2006).

869 For differential gene expression analysis of single cell data, we ran FindMarkers
870 or FindAllMarkers function in Seurat which allows for the evaluation of differentially
871 expressed genes between cell populations of interest. For each gene evaluated, the log
872 base 2 of the fold change between the population of interest and the comparator
873 population was calculated along with the adjusted p-values based on Bonferroni
874 correction using all the genes in the dataset.

875 To identify differential expression of genes along distinct differentiation branches
876 during the STREAM analysis, we conducted the leaf gene detection which involves
877 calculating the average gene expression of genes along the leaves of the
878 developmental trajectory. Detailed explanation for the statistical calculations conducted
879 by the STREAM package to find differentially expressed genes along differentiation
880 branches can be found in the original STREAM publication (Chen et al., 2019).

881

882 **Data and Code Availability Statement**

883 All raw data for single cell RNA-sequencing has been deposited in the GEO
884 repository under accession number GSE202398. Accession numbers for publicly
885 available data re-analyzed for this study can be found in **Figure 4-Source Data 1**.
886 Standard code and functions used for single cell analysis are available at the following

887 Github repositories: Seurat (<https://github.com/satijalab/seurat/>), ScanPy
888 (<https://github.com/scverse/scanpy>), STREAM (<https://github.com/pinellolab/STREAM>),
889 SoupX (<https://github.com/constantAmateur/SoupX>), CellRanger
890 (https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/using/tutorial_ov).

892

893 **ACKNOWLEDGEMENTS**

894 We would like to thank all members of the Sean Wu laboratory for their input and
895 feedback in the work presented in this manuscript. A special thanks to the members of
896 the Stanford Stem Cell Institute Flow Cytometry Core facility for their training and
897 experimental advice. We would also like to thank Sneha Venkatramen and Daniel Lee
898 for their assistance in supply management in the laboratory. We thank Vittorio
899 Sebastiano's laboratory for providing us access to the Stem Cell Core electroporation
900 equipment for genome editing experiments.

901

902 **FUNDING**

903 This work was supported by the NIH/NIGMS grant 1RM1 GM131981-02, American
904 Heart Association - Established Investigator Award, Hoffmann/Schroepfer Foundation,
905 Additional Venture Foundation, Joan and Sanford I. Weill Scholar Fund, and NIH/NHLBI
906 grant R01HL13483004 (S.M.W). This work was also supported by the NIH K08
907 Mentored Clinical Scientist Research Career Development Award (NHLBI)
908 (1K08HL15378501) (W.R.G.) and NIH/NHLBI F30HL149152 grant, the Dorothy Dee and

909 Marjorie Boring Trust Award, and the Stanford Medical Scientist Training Program
910 (F.X.G.).

911

912 **REFERENCES**

913 Andersen, P., Tampakakis, E., Jimenez, D.V., Kannan, S., Miyamoto, M., Shin, H.K.,
914 Saberi, A., Murphy, S., Sulistio, E., Chelko, S.P., Kwon, C., 2018. Precardiac
915 organoids form two heart fields via Bmp/Wnt signaling. *Nat Commun* 9, 3140.
916 <https://doi.org/10.1038/s41467-018-05604-8>

917 Barnes, R.M., Firulli, B.A., Conway, S.J., Vincentz, J.W., Firulli, A.B., 2010. Analysis of
918 the Hand1 Cell Lineage Reveals Novel Contributions to Cardiovascular, Neural
919 Crest, Extra-Embryonic, and Lateral Mesoderm Derivatives. *Dev Dyn* 239, 3086–
920 3097. <https://doi.org/10.1002/dvdy.22428>

921 Bizy, A., Guerrero-Serna, G., Hu, B., Ponce-Balbuena, D., Willis, B.C., Zarzoso, M.,
922 Ramirez, R.J., Sener, M.F., Mundada, L.V., Klos, M., Devaney, E.J., Vikstrom,
923 K.L., Herron, T.J., Jalife, J., 2013. Myosin light chain 2-based selection of human
924 iPSC-derived early ventricular cardiac myocytes. *Stem Cell Res* 11, 1335–1347.
925 <https://doi.org/10.1016/j.scr.2013.09.003>

926 Bruneau, B.G., Logan, M., Davis, N., Levi, T., Tabin, C.J., Seidman, J.G., Seidman,
927 C.E., 1999. Chamber-specific cardiac expression of Tbx5 and heart defects in
928 Holt-Oram syndrome. *Dev Biol* 211, 100–108.
929 <https://doi.org/10.1006/dbio.1999.9298>

930 Bruneau, B.G., Nemer, G., Schmitt, J.P., Charron, F., Robitaille, L., Caron, S., Conner,
931 D.A., Gessler, M., Nemer, M., Seidman, C.E., Seidman, J.G., 2001. A Murine
932 Model of Holt-Oram Syndrome Defines Roles of the T-Box Transcription Factor
933 Tbx5 in Cardiogenesis and Disease. *Cell* 106, 709–721.
934 [https://doi.org/10.1016/S0092-8674\(01\)00493-7](https://doi.org/10.1016/S0092-8674(01)00493-7)

935 Buckingham, M., Meilhac, S., Zaffran, S., 2005. Building the mammalian heart from two
936 sources of myocardial cells. *Nat Rev Genet* 6, 826–835.
937 <https://doi.org/10.1038/nrg1710>

938 Burridge, P.W., Holmström, A., Wu, J.C., 2015. Chemically Defined Culture and
939 Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. *Curr Protoc Hum
940 Genet* 87, 21.3.1-21.3.15. <https://doi.org/10.1002/0471142905.hg2103s87>

941 Cai, C.-L., Liang, X., Shi, Y., Chu, P.-H., Pfaff, S.L., Chen, J., Evans, S., 2003. Isl1
942 identifies a cardiac progenitor population that proliferates prior to differentiation
943 and contributes a majority of cells to the heart. *Dev Cell* 5, 877–889.
944 [https://doi.org/10.1016/s1534-5807\(03\)00363-0](https://doi.org/10.1016/s1534-5807(03)00363-0)

945 Chapman, D.L., Garvey, N., Hancock, S., Alexiou, M., Agulnik, S.I., Gibson-Brown, J.J.,
946 Cebra-Thomas, J., Bollag, R.J., Silver, L.M., Papaioannou, V.E., 1996.
947 Expression of the T-box family genes, Tbx1-Tbx5, during early mouse
948 development. *Dev Dyn* 206, 379–390. [https://doi.org/10.1002/\(SICI\)1097-0177\(199608\)206:4<379::AID-AJA4>3.0.CO;2-F](https://doi.org/10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F)

950 Chen, H., Albergante, L., Hsu, J.Y., Lareau, C.A., Lo Bosco, G., Guan, J., Zhou, S.,
951 Gorban, A.N., Bauer, D.E., Aryee, M.J., Langenau, D.M., Zinovyev, A.,
952 Buenrostro, J.D., Yuan, G.-C., Pinello, L., 2019. Single-cell trajectories
953 reconstruction, exploration and mapping of omics data with STREAM. *Nat
954 Commun* 10, 1903. <https://doi.org/10.1038/s41467-019-09670-4>

955 Chen, I.Y., Matsa, E., Wu, J.C., 2016. Induced Pluripotent Stem Cells: at the Heart of
956 Cardiovascular Precision Medicine. *Nat Rev Cardiol* 13, 333–349.
957 <https://doi.org/10.1038/nrcardio.2016.36>

958 Chirikian, O., Goodyer, W.R., Dzilic, E., Serpooshan, V., Buikema, J.W., McKeithan, W.,
959 Wu, H., Li, G., Lee, S., Merk, M., Galdos, F., Beck, A., Ribeiro, A.J.S., Paige, S.,
960 Mercola, M., Wu, J.C., Pruitt, B.L., Wu, S.M., 2021. CRISPR/Cas9-based
961 targeting of fluorescent reporters to human iPSCs to isolate atrial and ventricular-
962 specific cardiomyocytes. *Sci Rep* 11, 3026. [https://doi.org/10.1038/s41598-021-81860-x](https://doi.org/10.1038/s41598-021-
963 81860-x)

964 Christoffels, V.M., Grieskamp, T., Norden, J., Mommersteeg, M.T.M., Rudat, C., Kispert,
965 A., 2009. Tbx18 and the fate of epicardial progenitors. *Nature* 458, E8–E9.
966 <https://doi.org/10.1038/nature07916>

967 Cui, Y., Zheng, Y., Liu, X., Yan, L., Fan, X., Yong, J., Hu, Y., Dong, J., Li, Q., Wu, X.,
968 Gao, S., Li, J., Wen, L., Qiao, J., Tang, F., 2019. Single-Cell Transcriptome
969 Analysis Maps the Developmental Track of the Human Heart. *Cell Rep* 26, 1934–
970 1950.e5. <https://doi.org/10.1016/j.celrep.2019.01.079>

971 de Soysa, T.Y., Ranade, S.S., Okawa, S., Ravichandran, S., Huang, Y., Salunga, H.T.,
972 Schricker, A., del Sol, A., Gifford, C.A., Srivastava, D., 2019. Single-cell analysis
973 of cardiogenesis reveals basis for organ-level developmental defects. *Nature*
974 572, 120–124. <https://doi.org/10.1038/s41586-019-1414-x>

975 DeLaughter, D.M., Bick, A.G., Wakimoto, H., McKean, D., Gorham, J.M., Kathiriya, I.S.,
976 Hinson, J.T., Homsy, J., Gray, J., Pu, W., Bruneau, B.G., Seidman, J.G.,
977 Seidman, C.E., 2016. Single-Cell Resolution of Temporal Gene Expression
978 during Heart Development. *Developmental Cell* 39, 480–490.
979 <https://doi.org/10.1016/j.devcel.2016.10.001>

980 Délot, E.C., Bahamonde, M.E., Zhao, M., Lyons, K.M., 2003. BMP signaling is required
981 for septation of the outflow tract of the mammalian heart. *Development* 130, 209–
982 220. <https://doi.org/10.1242/dev.00181>

983 Devine, W.P., Wythe, J.D., George, M., Koshiba-Takeuchi, K., Bruneau, B.G., 2014.
984 Early patterning and specification of cardiac progenitors in gastrulating
985 mesoderm. *eLife* 3, e03848. <https://doi.org/10.7554/eLife.03848>

986 Doyle, M.J., Lohr, J.L., Chapman, C.S., Koyano-Nakagawa, N., Garry, M.G., Garry,
987 D.J., 2015. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a
988 Model for Heart Development and Congenital Heart Disease. *Stem Cell Rev and
989 Rep* 11, 710–727. <https://doi.org/10.1007/s12015-015-9596-6>

990 Drakhlis, L., Biswanath, S., Farr, C.-M., Luponow, V., Teske, J., Ritzenhoff, K., Franke,
991 A., Manstein, F., Bolesani, E., Kempf, H., Liebscher, S., Schenke-Layland, K.,
992 Hegermann, J., Nolte, L., Meyer, H., de la Roche, J., Thiemann, S., Wahl-Schott,
993 C., Martin, U., Zweigerdt, R., 2021. Human heart-forming organoids recapitulate
994 early heart and foregut development. *Nat Biotechnol* 39, 737–746.
995 <https://doi.org/10.1038/s41587-021-00815-9>

996 Dyer, L.A., Kirby, M.L., 2009. The role of secondary heart field in cardiac development.
997 *Developmental Biology* 336, 137–144.
998 <https://doi.org/10.1016/j.ydbio.2009.10.009>

999 Feyen, D.A.M., McKeithan, W.L., Bruyneel, A.A.N., Spiering, S., Hörmann, L., Ulmer,
1000 B., Zhang, H., Briganti, F., Schweizer, M., Hegyi, B., Liao, Z., Pölönen, R.-P.,
1001 Ginsburg, K.S., Lam, C.K., Serrano, R., Wahlquist, C., Kreymerman, A., Vu, M.,
1002 Amatya, P.L., Behrens, C.S., Ranjbarvaziri, S., Maas, R.G.C., Greenhaw, M.,
1003 Bernstein, D., Wu, J.C., Bers, D.M., Eschenhagen, T., Metallo, C.M., Mercola,
1004 M., 2020. Metabolic Maturation Media Improve Physiological Function of Human
1005 iPSC-Derived Cardiomyocytes. *Cell Rep* 32, 107925.
1006 <https://doi.org/10.1016/j.celrep.2020.107925>

1007 Galdos, F.X., Darsha, A.K., Paige, S.L., Wu, S.M., 2021. Purification of Pluripotent Stem
1008 Cell-Derived Cardiomyocytes Using CRISPR/Cas9-Mediated Integration of
1009 Fluorescent Reporters. *Methods Mol Biol* 2158, 223–240.
1010 https://doi.org/10.1007/978-1-0716-0668-1_17

1011 Haghverdi, L., Lun, A.T.L., Morgan, M.D., Marioni, J.C., 2018. Batch effects in single-
1012 cell RNA-sequencing data are corrected by matching mutual nearest neighbors.
1013 *Nat Biotechnol* 36, 421–427. <https://doi.org/10.1038/nbt.4091>

1014 Hikspoors, J.P.J.M., Kruepunga, N., Mommen, G.M.C., Köhler, S.E., Anderson, R.H.,
1015 Lamers, W.H., 2022. A pictorial account of the human embryonic heart between
1016 3.5 and 8 weeks of development. *Commun Biol* 5, 1–22.
1017 <https://doi.org/10.1038/s42003-022-03153-x>

1018 Hill, M.C., Kadow, Z.A., Li, L., Tran, T.T., Wythe, J.D., Martin, J.F., 2019. A cellular atlas
1019 of Pitx2-dependent cardiac development. *Development* 146, dev180398.
1020 <https://doi.org/10.1242/dev.180398>

1021 Holloway, E.M., Wu, J.H., Czerwinski, M., Sweet, C.W., Wu, A., Tsai, Y.-H., Huang, S.,
1022 Stoddard, A.E., Capeling, M.M., Glass, I., Spence, J.R., 2020. Differentiation of
1023 Human Intestinal Organoids with Endogenous Vascular Endothelial Cells.
1024 *Developmental Cell* 54, 516-528.e7. <https://doi.org/10.1016/j.devcel.2020.07.023>

1025 Hu, H., Lin, S., Wang, S., Chen, X., 2020. The Role of Transcription Factor 21 in
1026 Epicardial Cell Differentiation and the Development of Coronary Heart Disease.
1027 *Front Cell Dev Biol* 8, 457. <https://doi.org/10.3389/fcell.2020.00457>

1028 Hurrell, T., Segeritz, C.-P., Vallier, L., Lilley, K.S., Cromarty, A.D., 2019. A proteomic
1029 time course through the differentiation of human induced pluripotent stem cells
1030 into hepatocyte-like cells. *Sci Rep* 9, 3270. <https://doi.org/10.1038/s41598-019-39400-1>

1032 Hyun, I., Bredenoord, A.L., Briscoe, J., Klipstein, S., Tan, T., 2021. Human embryo
1033 research beyond the primitive streak. *Science* 371, 998–1000.
1034 <https://doi.org/10.1126/science.abf3751>

1035 Kanton, S., Boyle, M.J., He, Z., Santel, M., Weigert, A., Sanchís-Calleja, F., Guijarro, P.,
1036 Sidow, L., Fleck, J.S., Han, D., Qian, Z., Heide, M., Huttner, W.B., Khaitovich, P.,
1037 Pääbo, S., Treutlein, B., Camp, J.G., 2019. Organoid single-cell genomic atlas
1038 uncovers human-specific features of brain development. *Nature* 574, 418–422.
1039 <https://doi.org/10.1038/s41586-019-1654-9>

1040 Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue,
1041 H., Yamashita, J.K., Todani, M., Nakagawa, M., Osawa, M., Yashiro, Y.,

1042 Yamanaka, S., Osafune, K., 2019. Induced Pluripotent Stem Cells and Their Use
1043 in Human Models of Disease and Development. *Physiological Reviews* 99, 79–
1044 114. <https://doi.org/10.1152/physrev.00039.2017>

1045 Kelly, R.G., Brown, N.A., Buckingham, M.E., 2001. The Arterial Pole of the Mouse Heart
1046 Forms from Fgf10-Expressing Cells in Pharyngeal Mesoderm. *Developmental
1047 Cell* 1, 435–440. [https://doi.org/10.1016/S1534-5807\(01\)00040-5](https://doi.org/10.1016/S1534-5807(01)00040-5)

1048 Khosravi, F., Ahmadvand, N., Bellusci, S., Sauer, H., 2021. The Multifunctional
1049 Contribution of FGF Signaling to Cardiac Development, Homeostasis, Disease
1050 and Repair. *Frontiers in Cell and Developmental Biology* 9.

1051 Lescroart, F., Chabab, S., Lin, X., Rulands, S., Paulissen, C., Rodolosse, A., Auer, H.,
1052 Achouri, Y., Dubois, C., Bondu, A., Simons, B.D., Blanpain, C., 2014. Early
1053 lineage restriction in temporally distinct populations of Mesp1 progenitors during
1054 mammalian heart development. *Nat Cell Biol* 16, 829–840.
1055 <https://doi.org/10.1038/ncb3024>

1056 Li, G., Tian, L., Goodyer, W., Kort, E.J., Buikema, J.W., Xu, A., Wu, J.C., Jovinge, S.,
1057 Wu, S.M., 2019. Single cell expression analysis reveals anatomical and cell
1058 cycle-dependent transcriptional shifts during heart development. *Development*
1059 146. <https://doi.org/10.1242/dev.173476>

1060 Li, G., Xu, A., Sim, S., Priest, J.R., Tian, X., Khan, T., Quertermous, T., Zhou, B., Tsao,
1061 P.S., Quake, S.R., Wu, S.M., 2016. Transcriptomic Profiling Maps Anatomically
1062 Patterned Subpopulations among Single Embryonic Cardiac Cells.
1063 *Developmental Cell* 39, 491–507. <https://doi.org/10.1016/j.devcel.2016.10.014>

1064 Li, P., Cavallero, S., Gu, Y., Chen, T.H.P., Hughes, J., Hassan, A.B., Brüning, J.C.,
1065 Pashmforoush, M., Sucov, H.M., 2011. IGF signaling directs ventricular
1066 cardiomyocyte proliferation during embryonic heart development. *Development*
1067 138, 1795–1805. <https://doi.org/10.1242/dev.054338>

1068 Lian, X., Zhang, J., Azarin, S.M., Zhu, K., Hazeltine, L.B., Bao, X., Hsiao, C., Kamp,
1069 T.J., Palecek, S.P., 2013. Directed cardiomyocyte differentiation from human
1070 pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined
1071 conditions. *Nat Protoc* 8, 162–175. <https://doi.org/10.1038/nprot.2012.150>

1072 Liao, J., Aggarwal, V.S., Nowotschin, S., Bondarev, A., Lipner, S., Morrow, B.E., 2008.
1073 Identification of downstream genetic pathways of Tbx1 in the second heart field.
1074 *Developmental Biology* 316, 524–537.
1075 <https://doi.org/10.1016/j.ydbio.2008.01.037>

1076 Liu, Z., Chen, O., Wall, J.B.J., Zheng, M., Zhou, Y., Wang, L., Ruth Vaseghi, H., Qian,
1077 L., Liu, J., 2017. Systematic comparison of 2A peptides for cloning multi-genes in
1078 a polycistronic vector. *Sci Rep* 7, 2193. [https://doi.org/10.1038/s41598-017-02460-2](https://doi.org/10.1038/s41598-017-
1079 02460-2)

1080 Ma, H.-Y., Xu, J., Eng, D., Gross, M.K., Kioussi, C., 2013. Pitx2-mediated cardiac
1081 outflow tract remodeling. *Dev Dyn* 242, 456–468.
1082 <https://doi.org/10.1002/dvdy.23934>

1083 Ma, Q., Zhou, B., Pu, W.T., 2008. Reassessment of Isl1 and Nkx2-5 cardiac fate maps
1084 using a Gata4-based reporter of Cre activity. *Dev Biol* 323, 98–104.
1085 <https://doi.org/10.1016/j.ydbio.2008.08.013>

1086 Mead, P.E., Brivanlou, I.H., Kelley, C.M., Zon, L.I., 1996. BMP-4-responsive regulation
1087 of dorsal-ventral patterning by the homeobox protein Mix.1. *Nature* 382, 357–
1088 360. <https://doi.org/10.1038/382357a0>

1089 Meilhac, S.M., Buckingham, M.E., 2018. The deployment of cell lineages that form the
1090 mammalian heart. *Nat Rev Cardiol* 15, 705–724. <https://doi.org/10.1038/s41569-018-0086-9>

1092 Meilhac, S.M., Esner, M., Kelly, R.G., Nicolas, J.-F., Buckingham, M.E., 2004. The
1093 clonal origin of myocardial cells in different regions of the embryonic mouse
1094 heart. *Dev Cell* 6, 685–698. [https://doi.org/10.1016/s1534-5807\(04\)00133-9](https://doi.org/10.1016/s1534-5807(04)00133-9)

1095 Mesbah, K., Rana, M.S., Francou, A., van Duijvenboden, K., Papaioannou, V.E.,
1096 Moorman, A.F., Kelly, R.G., Christoffels, V.M., 2012. Identification of a
1097 *Tbx1/Tbx2/Tbx3* genetic pathway governing pharyngeal and arterial pole
1098 morphogenesis. *Hum Mol Genet* 21, 1217–1229.
1099 <https://doi.org/10.1093/hmg/ddr553>

1100 Mjaatvedt, C.H., Nakaoka, T., Moreno-Rodriguez, R., Norris, R.A., Kern, M.J.,
1101 Eisenberg, C.A., Turner, D., Markwald, R.R., 2001. The Outflow Tract of the
1102 Heart Is Recruited from a Novel Heart-Forming Field. *Developmental Biology*
1103 238, 97–109. <https://doi.org/10.1006/dbio.2001.0409>

1104 Moretti, A., Caron, L., Nakano, A., Lam, J.T., Bernshausen, A., Chen, Y., Qyang, Y., Bu,
1105 L., Sasaki, M., Martin-Puig, S., Sun, Y., Evans, S.M., Laugwitz, K.-L., Chien,
1106 K.R., 2006. Multipotent Embryonic *Isl1*+ Progenitor Cells Lead to Cardiac,
1107 Smooth Muscle, and Endothelial Cell Diversification. *Cell* 127, 1151–1165.
1108 <https://doi.org/10.1016/j.cell.2006.10.029>

1109 Motulsky, H.J., Brown, R.E., 2006. Detecting outliers when fitting data with nonlinear
1110 regression – a new method based on robust nonlinear regression and the false
1111 discovery rate. *BMC Bioinformatics* 7, 123. <https://doi.org/10.1186/1471-2105-7-123>

1113 Nelson, D.O., Jin, D.X., Downs, K.M., Kamp, T.J., Lyons, G.E., 2014. *Irx4* identifies a
1114 chamber-specific cell population that contributes to ventricular myocardium
1115 development. *Dev Dyn* 243, 381–392. <https://doi.org/10.1002/dvdy.24078>

1116 Nelson, D.O., Lalit, P.A., Biermann, M., Markandeya, Y.S., Capes, D.L., Addesso, L.,
1117 Patel, G., Han, T., John, M.C., Powers, P.A., Downs, K.M., Kamp, T.J., Lyons,
1118 G.E., 2016. *Irx4* marks a multipotent, ventricular-specific progenitor cell. *Stem
1119 Cells* 34, 2875–2888. <https://doi.org/10.1002/stem.2486>

1120 Nevis, K., Obregon, P., Walsh, C., Guner-Ataman, B., Burns, C.G., Burns, C.E., 2013.
1121 *Tbx1* is required for second heart field proliferation in zebrafish. *Dev Dyn* 242,
1122 550–559. <https://doi.org/10.1002/dvdy.23928>

1123 O'Brien, T.X., Lee, K.J., Chien, K.R., 1993. Positional specification of ventricular myosin
1124 light chain 2 expression in the primitive murine heart tube. *PNAS* 90, 5157–5161.
1125 <https://doi.org/10.1073/pnas.90.11.5157>

1126 Park, E.J., Watanabe, Y., Smyth, G., Miyagawa-Tomita, S., Meyers, E., Klingensmith,
1127 J., Camenisch, T., Buckingham, M., Moon, A.M., 2008. An FGF autocrine loop
1128 initiated in second heart field mesoderm regulates morphogenesis at the arterial
1129 pole of the heart. *Development* 135, 3599–3610.
1130 <https://doi.org/10.1242/dev.025437>

1131 Pijuan-Sala, B., Griffiths, J.A., Guibentif, C., Hiscock, T.W., Jawaid, W., Calero-Nieto,
1132 F.J., Mulas, C., Ibarra-Soria, X., Tyser, R.C.V., Ho, D.L.L., Reik, W., Srinivas, S.,
1133 Simons, B.D., Nichols, J., Marioni, J.C., Göttgens, B., 2019. A single-cell
1134 molecular map of mouse gastrulation and early organogenesis. *Nature* 566, 490–
1135 495. <https://doi.org/10.1038/s41586-019-0933-9>

1136 Protze, S.I., Lee, J.H., Keller, G.M., 2019a. Human Pluripotent Stem Cell-Derived
1137 Cardiovascular Cells: From Developmental Biology to Therapeutic Applications.
1138 *Cell Stem Cell* 25, 311–327. <https://doi.org/10.1016/j.stem.2019.07.010>

1139 Protze, S.I., Lee, J.H., Keller, G.M., 2019b. Human Pluripotent Stem Cell-Derived
1140 Cardiovascular Cells: From Developmental Biology to Therapeutic Applications.
1141 *Cell Stem Cell* 25, 311–327. <https://doi.org/10.1016/j.stem.2019.07.010>

1142 Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., 2013. Genome
1143 engineering using the CRISPR-Cas9 system. *Nat Protoc* 8, 2281–2308.
1144 <https://doi.org/10.1038/nprot.2013.143>

1145 Rana, M.S., Théveniau-Ruissy, M., De Bono, C., Mesbah, K., Francou, A., Rammah,
1146 M., Domínguez, J.N., Roux, M., Laforest, B., Anderson, R.H., Mohun, T., Zaffran,
1147 S., Christoffels, V.M., Kelly, R.G., 2014. Tbx1 coordinates addition of posterior
1148 second heart field progenitor cells to the arterial and venous poles of the heart.
1149 *Circ Res* 115, 790–799. <https://doi.org/10.1161/CIRCRESAHA.115.305020>

1150 Reifers, F., Walsh, E.C., Léger, S., Stainier, D.Y., Brand, M., 2000. Induction and
1151 differentiation of the zebrafish heart requires fibroblast growth factor 8
1152 (fgf8/acerebellar). *Development* 127, 225–235.
1153 <https://doi.org/10.1242/dev.127.2.225>

1154 Reller, M.D., Strickland, M.J., Riehle-Colarusso, T., Mahle, W.T., Correa, A., 2008.
1155 Prevalence of Congenital Heart Defects in Metropolitan Atlanta, 1998–2005. *The
1156 Journal of Pediatrics* 153, 807–813. <https://doi.org/10.1016/j.jpeds.2008.05.059>

1157 Rochais, F., Mesbah, K., Kelly, R.G., 2009. Signaling Pathways Controlling Second
1158 Heart Field Development. *Circulation Research* 104, 933–942.
1159 <https://doi.org/10.1161/CIRCRESAHA.109.194464>

1160 Rossi, G., Broguiere, N., Miyamoto, M., Boni, A., Guiet, R., Girgin, M., Kelly, R.G.,
1161 Kwon, C., Lutolf, M.P., 2021. Capturing Cardiogenesis in Gastruloids. *Cell Stem
1162 Cell* 28, 230–240.e6. <https://doi.org/10.1016/j.stem.2020.10.013>

1163 Rudat, C., Kispert, A., 2012. Wt1 and Epicardial Fate Mapping. *Circulation Research*
1164 111, 165–169. <https://doi.org/10.1161/CIRCRESAHA.112.273946>

1165 Sacchetto, C., Vitiello, L., de Windt, L.J., Rampazzo, A., Calore, M., 2020. Modeling
1166 Cardiovascular Diseases with hiPSC-Derived Cardiomyocytes in 2D and 3D
1167 Cultures. *Int J Mol Sci* 21, 3404. <https://doi.org/10.3390/ijms21093404>

1168 Saga, Y., Miyagawa-Tomita, S., Takagi, A., Kitajima, S., Miyazaki, J. i, Inoue, T., 1999.
1169 MesP1 is expressed in the heart precursor cells and required for the formation of
1170 a single heart tube. *Development* 126, 3437–3447.

1171 Sarrach, S., Huang, Y., Niedermeyer, S., Hachmeister, M., Fischer, L., Gille, S., Pan,
1172 M., Mack, B., Kranz, G., Libl, D., Merl-Pham, J., Hauck, S.M., Paoluzzi Tomada,
1173 E., Kieslinger, M., Jeremias, I., Scialdone, A., Gires, O., 2018. Spatiotemporal
1174 patterning of EpCAM is important for murine embryonic endo- and mesodermal
1175 differentiation. *Sci Rep* 8, 1801. <https://doi.org/10.1038/s41598-018-20131-8>

1176 Schleiffarth, J.R., Person, A.D., Martinsen, B.J., Sukovich, D.J., Neumann, A., Baker,
1177 C.V.H., Lohr, J.L., Cornfield, D.N., Ekker, S.C., Petryk, A., 2007. *Wnt5a* is
1178 required for cardiac outflow tract septation in mice. *Pediatr Res* 61, 386–391.
1179 <https://doi.org/10.1203/pdr.0b013e3180323810>

1180 Scialdone, A., Tanaka, Y., Jawaid, W., Moignard, V., Wilson, N.K., Macaulay, I.C.,
1181 Marioni, J.C., Göttgens, B., 2016. Resolving Early Mesoderm Diversification
1182 through Single Cell Expression Profiling. *Nature* 535, 289–293.
1183 <https://doi.org/10.1038/nature18633>

1184 Später, D., Abramczuk, M.K., Buac, K., Zangi, L., Stachel, M.W., Clarke, J., Sahara, M.,
1185 Ludwig, A., Chien, K.R., 2013. A HCN4+ cardiomyogenic progenitor derived from
1186 the first heart field and human pluripotent stem cells. *Nat Cell Biol* 15, 1098–
1187 1106. <https://doi.org/10.1038/ncb2824>

1188 Takahashi, K., Yamanaka, S., 2006. Induction of Pluripotent Stem Cells from Mouse
1189 Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell* 126, 663–676.
1190 <https://doi.org/10.1016/j.cell.2006.07.024>

1191 Tan, C.M.J., Lewandowski, A.J., 2020. The Transitional Heart: From Early Embryonic
1192 and Fetal Development to Neonatal Life. *FDT* 47, 373–386.
1193 <https://doi.org/10.1159/000501906>

1194 Tandon, P., Miteva, Y.V., Kuchenbrod, L.M., Cristea, I.M., Conlon, F.L., 2013. *Tcf21*
1195 regulates the specification and maturation of proepicardial cells. *Development*
1196 140, 2409–2421. <https://doi.org/10.1242/dev.093385>

1197 Tyser, R.C.V., Ibarra-Soria, X., McDole, K., Jayaram, S.A., Godwin, J., Brand, T.A.H.
1198 van den, Miranda, A.M.A., Scialdone, A., Keller, P.J., Marioni, J.C., Srinivas, S.,
1199 2020. Characterization of a common progenitor pool of the epicardium and
1200 myocardium. *Science*. <https://doi.org/10.1126/science.abb2986>

1201 Tyser, R.C.V., Mahammadov, E., Nakanoh, S., Vallier, L., Scialdone, A., Srinivas, S.,
1202 2021. Single-cell transcriptomic characterization of a gastrulating human embryo.
1203 *Nature* 600, 285–289. <https://doi.org/10.1038/s41586-021-04158-y>

1204 van der Linde, D., Konings, E.E.M., Slager, M.A., Witsenburg, M., Helbing, W.A.,
1205 Takkenberg, J.J.M., Roos-Hesselink, J.W., 2011. Birth prevalence of congenital
1206 heart disease worldwide: a systematic review and meta-analysis. *J Am Coll
1207 Cardiol* 58, 2241–2247. <https://doi.org/10.1016/j.jacc.2011.08.025>

1208 Vincentz, J.W., Toolan, K.P., Zhang, W., Firulli, A.B., 2017. Hand factor ablation causes
1209 defective left ventricular chamber development and compromised adult cardiac
1210 function. *PLOS Genetics* 13, e1006922.
1211 <https://doi.org/10.1371/journal.pgen.1006922>

1212 Vitelli, F., Morishima, M., Taddei, I., Lindsay, E.A., Baldini, A., 2002. *Tbx1* mutation
1213 causes multiple cardiovascular defects and disrupts neural crest and cranial
1214 nerve migratory pathways. *Human Molecular Genetics* 11, 915–922.
1215 <https://doi.org/10.1093/hmg/11.8.915>

1216 Waldo, K.L., Kumiski, D.H., Wallis, K.T., Stadt, H.A., Hutson, M.R., Platt, D.H., Kirby,
1217 M.L., 2001. Conotruncal myocardium arises from a secondary heart field.
1218 *Development* 128, 3179–3188. <https://doi.org/10.1242/dev.128.16.3179>

1219 Wolf, F.A., Angerer, P., Theis, F.J., 2018. SCANPY: large-scale single-cell gene
1220 expression data analysis. *Genome Biology* 19, 15.
1221 <https://doi.org/10.1186/s13059-017-1382-0>

1222 Xiong, H., Luo, Y., Yue, Y., Zhang, J., Ai, S., Li, X., Wang, X., Zhang, Y.-L., Wei, Y., Li,
1223 H.-H., Hu, X., Li, C., He, A., 2019. Single-Cell Transcriptomics Reveals
1224 Chemotaxis-Mediated Intraorgan Crosstalk During Cardiogenesis. *Circ Res* 125,
1225 398–410. <https://doi.org/10.1161/CIRCRESAHA.119.315243>

1226 Yamanaka, S., 2008. Induction of pluripotent stem cells from mouse fibroblasts by four
1227 transcription factors. *Cell Proliferation* 41, 51–56. <https://doi.org/10.1111/j.1365-2184.2008.00493.x>

1229 Young, M.D., Behjati, S., 2020. SoupX removes ambient RNA contamination from
1230 droplet-based single-cell RNA sequencing data. *GigaScience* 9.
1231 <https://doi.org/10.1093/gigascience/giaa151>

1232 Zeng, B., Ren, X., Cao, F., Zhou, X., Zhang, J., 2011. Developmental patterns and
1233 characteristics of epicardial cell markers *Tbx18* and *Wt1* in murine embryonic
1234 heart. *Journal of Biomedical Science* 18, 67. <https://doi.org/10.1186/1423-0127-18-67>

1236 Zhang, J.Z., Termglinchan, V., Shao, N.-Y., Itzhaki, I., Liu, C., Ma, N., Tian, L., Wang,
1237 V.Y., Chang, A.C.Y., Guo, H., Kitani, T., Wu, H., Lam, C.K., Kodo, K., Sayed, N.,
1238 Blau, H.M., Wu, J.C., 2019. A Human iPSC Double-Reporter System Enables
1239 Purification of Cardiac Lineage Subpopulations with Distinct Function and Drug
1240 Response Profiles. *Cell Stem Cell* 24, 802-811.e5.
1241 <https://doi.org/10.1016/j.stem.2019.02.015>

1242 Zhang, Q., Carlin, D., Zhu, F., Cattaneo, P., Ideker, T., Evans, S.M., Bloomekatz, J.,
1243 Chi, N.C., 2021. Unveiling Complexity and Multipotentiality of Early Heart Fields.
1244 *Circulation Research* 129, 474–487.
1245 <https://doi.org/10.1161/CIRCRESAHA.121.318943>

1246

1247 **Figure Legends**

1248 **Figure 1: Integration of TBX5/MYL2 Lineage Tracing Reporter System into Human**
1249 **Induced Pluripotent Stem Cells**

1250

1251 (A) Schematic of lineage tracing strategy for identifying left ventricular
1252 cardiomyocytes *in vitro*.

1253 (B) CRISPR/Cas9 gene targeting strategy of genetic constructs for TBX5 lineage
1254 tracing and MYL2 direct reporter. MYL2, CCR5, and TBX5 constructs contain
1255 Puromycin (PuroR), Neomycin (NeoR), and Hygromycin (HygroR) resistance
1256 cassettes for selection of hiPSC after targeting of genetic constructs. Blue arrows
1257 indicate location of PCR primer binding sites for confirmation of construct
1258 integration. LHA= Left Homology Arm, RHA = Right Homology Arm.

1259 (C) Inside-Outside (I/O) and Outside-Outside (O/O) PCR DNA agarose gels for
1260 confirmation of integration of genetic constructs into MYL2, CCR5, and TBX5
1261 genetic loci. Inside, represents a primer inside the construct region while Outside
1262 represents a primer that binds outside the homology arm regions of genetic
1263 constructs. Expected band sizes are noted with arrows for each lane.

1264 (D) Sanger sequencing traces for C-terminal regions of MYL2 and TBX5 genes
1265 indicating in-frame integration of P2A site.

1266 (E) Bright field and immunofluorescence images of pluripotency marker expression
1267 in hiPSC lines after integration of all three genetic constructs.
1268

1269 **Figure 2: TBX5-Lineage Tracing Reveals a Predominance of Lineage Positive**
1270 **Cardiomyocytes Through the Course of HiPSC Cardiac Differentiation**

1271 (A) Schematic of analysis approach of reporter system expression through the
1272 course of cardiac differentiation.
1273 (B) Representative flow cytometry plots for the expression of TurboGFP and cardiac
1274 troponin T staining between Day 3 to Day 30 of differentiation for WTC and
1275 SCVI-111 reporter lines. Gating set based on Day 3 of differentiation.
1276 (C) Representative flow cytometry for the expression MYL2-tdTomato and TurboGFP
1277 between Day 3 and Day 30. Gating set based on Day 3 of differentiation.
1278 (D) Quantification of percentage cardiac troponin T (TNNT2) expressing cells across
1279 all cells sampled.
1280 (E) Quantification of the percentage of TurboGFP positive cells out of cardiac
1281 troponin positive cardiomyocytes.
1282 (F) Quantification of tdTomato expressing cells across total cells sampled.
1283 Quantification of TurboGFP-positive cells out of MYL2-Tdtomato cardiomyocytes
1284 Minimum of 4 independent differentiations collected per sample. *pvalue<0.05,
1285 **pvalue<0.01, ***pvalue<0.001, ****pvalue<0.0001. Error bars represent standard
1286 error of the mean (SEM).

1287 **Figure 3: Immunofluorescence Imaging of Day 30 Reporter Cardiomyocytes and**
1288 **RT-qPCR Profiling of FHF and SHF Markers Across Differentiation**

1289 (A) Immunofluorescence images of TurboGFP, TdTomato, and TNNT2 expression at
1290 Day 30 of cardiac differentiation for WTC and SCVI-111 reporter lines.
1291 (B) RT-qPCR profiling of FHF markers HAND1 and TBX5 along with Cre
1292 Recombinase between Day 0 and Day 30 of differentiation.
1293 (C) RT-qPCR profiling of pan-cardiac progenitor marker ISL1, and SHF markers
1294 TBX1 and FGF8 between Day 0 and Day 30 of differentiation.
1295 (D) RT-qPCR profiling of pan-cardiomyocyte marker TNNT2.
1296 (E) RT-qPCR profiling of ventricular marker MYL2.
1297 N=3-4 biological replicates per timepoint. *pvalue<0.05, **pvalue<0.01,
1298 ***pvalue<0.001, ****pvalue<0.0001. Error bars represent standard error of the
1299 mean (SEM).

1300 **Figure 4: scRNA-seq Profiling and Trajectory Inference Reveals Emergence of**
1301 **Myocardial and Epicardial Lineages During hiPSC Cardiac Differentiation**

1302 (A) Diagram of scRNA-seq multiplexing for profiling of 12 timepoints across two lines
1303 during hiPSC cardiac differentiation.

1309 (B) Left, UMAP plot with identification of 13 cell populations over the course cardiac
1310 differentiation. Right-Top, Plot indicating labeling of cells captured from WTC and
1311 SCVI-111 line. Right-Bottom, Plot indicating timepoints of differentiation at which
1312 cells were captured for scRNA-seq.
1313 (C) Dotplot presenting expression of top markers for major cell populations identified
1314 during hiPSC cardiac differentiation.
1315 (D) Subway map plot showing projection of cells along cell lineages detected using
1316 STREAM analysis.
1317 (E) Stream plot indicating the relative cell type composition along each branch of
1318 differentiation identified by STREAM.
1319 (F) Graph indicating pseudotime values calculated by STREAM for ordering cells
1320 along a continuous developmental projection axis.
1321 (G) Feature plots for top gene markers identified during each major developmental
1322 phase of hiPSC cardiac differentiation.
1323

1324 **Figure 5: Comparison of Heart Field Development Between Murine and hiPSC**
1325 **Cardiac Differentiation Reveals FHF Identity of hiPSC Cardiac Lineages**

1326 (A) Top, UMAP plot showing clustering of murine cell types encompassing early
1327 mesodermal progenitors, FHF/SHF progenitors, LV/RV/OFT cardiomyocytes,
1328 and epicardial cells. Bottom-left, labeling of cell types by timepoint analyzed.
1329 Bottom-right, annotation by reference from which data was obtained.
1330 (B) UMAP embeddings of heart field development split by FHF and SHF lineages.
1331 (C) FHF and aSHF trajectory analysis and plotting of expression FHF (Tbx5 and
1332 Hcn4) and anterior SHF (Tbx1 and Fgf8) markers.
1333 (D) Analysis of FHF and aSHF marker expression during hiPSC cardiac
1334 differentiation.
1335 (E) Gene expression analysis of ventricular markers IRX4 and MYL2 during hiPSC
1336 cardiac differentiation.
1337 (F)

1338 **Figure 6: Comparison of 2D and 3D Cardiac Differentiation Uncovers Potential of**
1339 **Organoid System for SHF Generation**

1340 (A) Schematic of Comparison Strategy of scRNA-seq data from 2D hiPSC cardiac
1341 differentiation generated using our 2D protocol and a previously published
1342 organoid protocol.
1343 (B) UMAP plot of the myocardial lineage identified during 2D hiPSC cardiac
1344 differentiation.
1345 (C) Feature plots of FHF (TBX5, HCN4, HAND1), pan-cardiac (ISL1, NKX2-5,
1346 TNNI1), and SHF (FGF8, TBX1) during 2D hiPSC differentiation.
1347 (D) UMAP plot of Drakhlis et al cardiac lineage cells with annotation of unsupervised
1348 clusters.
1349 (E) Feature plots of FHF (TBX5, HCN4, HAND1), pan-cardiac (ISL1, NKX2-5,
1350 TNNI1), and SHF (FGF8, TBX1) during organoid differentiation

1353 (F) Co-clustering of 2D and 3D cardiomyocytes with annotation of source dataset
1354 (right-top) and expression of TBX5 (right-bottom).
1355 (G) Volcano plot for top differentially expressed genes between OFT identified
1356 cluster and remainder of identified cardiomyocytes identified as left ventricular.
1357

1358 **Supplementary File Legends**

1359 **Figure 1-figure supplement 1: Flow Cytometry analysis of TurboGFP expression**
1360 **in genome edited hiPSCs after 30 day of pluripotency culture.** Genome edited
1361 SCVI-111 and WTC were cultured in pluripotency media for 30 days. Flow cytometry
1362 plots shown for day 0 of culture and day 30 of culture.
1363

1364 **Figure 2-figure supplement 1: FACS Sorted TurboGFP Positive Cells Enrich for**
1365 **TBX5 Expression**

1366 (A) Representative FACS plot of sort GFP+ and GFP- Day 15 WTC reporter line
1367 cardiac differentiations.
1368 (B) RT-qPCR for TBX5 and TurboGFP expression of GFP+ and GFP- sorted Day 15
1369 WTC cardiac differentiations. N=4 independent biological replicates. ***p<0.001
1370 (C) Representative FACS plot of sort GFP+ and GFP- Day 15 SCVI-111 reporter line
1371 cardiac differentiations.
1372 (D) RT-qPCR for TBX5 and TurboGFP expression of GFP+ and GFP- sorted Day 15
1373 SCVI-111 cardiac differentiations. N=4 independent biological replicates.
1374 ***p<0.001
1375

1376 **Figure 4-figure supplement 1: Quality Control and Hashtag Oligo Labeling of**
1377 **Samples for scRNA-seq Sample Galdos_Seq_Run1**

1378 (A) Cutoff values (dotted red lines) calculated for quality control filtering of four
1379 metrics evaluated.
1380 (B) Ridge plots demonstrating highly specific labeling of chemically modified oligos
1381 for multiplexing of day 1-6 samples across two hiPSC lines.
1382

1383 **Figure 4-figure supplement 2: Quality Control and Hashtag Oligo Labeling of**
1384 **Samples for scRNA-seq Sample Galdos_Seq_Run2**

1385 (A) Cutoff values (dotted red lines) calculated for quality control filtering of four
1386 metrics evaluated.
1387 (B) Ridge plots demonstrating highly specific labeling of chemically modified oligos
1388 for multiplexing of day 0, 7, and 11 samples across two hiPSC lines.
1389

1390 **Figure 4-figure supplement 3: Quality Control and Hashtag Oligo Labeling of**
1391 **Samples for scRNA-seq Sample Galdos_Seq_Run3**

1392 (A) Cutoff values (dotted red lines) calculated for quality control filtering of four
1393 metrics evaluated.
1394 (B) Ridge plots demonstrating highly specific labeling of chemically modified oligos
1395 for multiplexing of day 13, 15, and 30 samples across two hiPSC lines.
1396

1397 **Figure 4-figure supplement 4: Unsupervised Clustering and Marker Expression of**
1398 **Combined hiPSC scRNA-seq Data from WTC and SCVI-111 lines.**

1399 (A) UMAP embedding for combined scRNA-seq data from WTC and SCVI-111 lines,
1400 along with unsupervised clustered identified.
1401 (B) Stacked violin plots for distinct cell markers enriched across all clusters identified.

1402
1403 **Figure 4-figure supplement 5: Trajectory Inference Analysis of hiPSC Cardiac**
1404 **Differentiation Across WTC and SCVI-111 Lines**

1405 (A) UMAP embedding reproduced from Figure 4A demonstrating annotation of 12
1406 distinct cell types.
1407 (B) Compositional analysis showing proportion of each cell type identified across all
1408 times points for both WTC and SCVI-111 lines.
1409 (C) STREAM algorithm fitting of principal graphs and trajectory inference detection.
1410 Cells were ordered along principal graphs and calculated pseudotime values.
1411 (D) Expression of statistically significant gene markers along differentiation
1412 trajectories identified during hiPSC cardiac differentiation.

1413
1414 **Figure 4-figure supplement 6: Feature Plots of Selected FHF, SHF, Endoderm, and**
1415 **Cardiomyocyte Markers**

1416 (A) UMAP of hiPSC cardiac differentiations showing cell type annotation, (B) cell line
1417 of origin, and (C) timepoint during differentiation.
1418 (D) Feature plots showing gene expression of selected genes in individual cells
1419 along UMAP plot.

1420
1421 **Figure 4-figure supplement 7: Comparison of Expression of Atrial and Ventricular**
1422 **Cardiomyocyte Markers in hiPSC-CM scRNA-seq Time Course**

1423 (A) UMAP of hiPSC cardiac differentiations showing cell type annotation, (B) cell line
1424 of origin, and (C) timepoint during differentiation.
1425 (D) Feature plots showing gene expression of atrial markers (KCNA5, NR2F1, and
1426 VSNL1) and ventricular markers (IRX4, MYH7, and MYL2).

1427
1428 **Videos:**

1429
1430 **Video 1: Contractility of SCVI-111 reporter line cardiomyocytes at Day 15 of**
1431 **differentiation.**






1432
1433 **Video 2: Contractility of WTC reporter line cardiomyocytes at Day 15 of**
1434 **differentiation.**








1435
1436 **Source Data:**











1437
1438 **Figure 1-Source Data 1:** Raw and uncropped DNA electrophoresis image data for
1439 genotyping PCR for genetic constructs presented in Figure 1C.








1440
1441 **Figure 1-Source Data 2:** Single Guide RNA Sequences Used for Gene Targeting


1443
1444 **Figure 1-Source Data 3:** Genotyping Primer Sequences for Identification of Genetic
1445 Constructs
1446
1447 **Figure 3-Source Data 1:** qPCR Human Primer Sequences
1448
1449 **Figure 4-Source Data 1:** GEO Accession Numbers for Datasets
1450
1451 **Figure 4-Source Data 2:** Differentially Expressed Genes Identified For Annotated Cell
1452 Types
1453
1454 **Figure 4-Source Data 3:** Genes Correlated with Differentiation Trajectories Identified
1455 During hiPSC Cardiac Differentiation
1456
1457 **Figure 4-Source Data 4:** Description of scRNA-seq Run and Hashtag Oligo Sequences
1458 Used for Sample Multiplexing
1459
1460 **Figure 6-Source Data 1:** Differential Gene Expression Analysis Between Putative OFT
1461 and LV cardiomyocyte clusters in Joint 2D and 3D hiPSC-CM Data. Pct1 and Pct2
1462 represent percentage of cells in Cluster 1 and All Other that express a particular gene.
1463

A**B****C****D****E**


A**B****C****D****E****F****G**

A**B****HAND1****TBX5****Cre****C****ISL1****FGF8****TBX1****D****TNNT2****MYL2****MYH7**● WTC ● SCVI-111

A**B****C****D****E****F****STREAM Pseudotime****G**




Timepoint




Reference

● Hill_et.al_2019
● Pijuan_sala_et.al_2019
● deSoya_et.al


aSHF Lineage




C




FHF Markers




aSHF Markers




D



FHF Markers




aSHF Markers











E

IRX4




MYL2




A**B****C****D****E****F****G****Cluster 1 (OFT) vs All (LV CM)**

Day 0 of Culture




Day 30 of Culture




WTC





Day 0 of Culture







Day 30 of Culture







SCVI-111




A**B****C****D**

A**B**




A**B**

A**B**




A**B**

A**B****C****D**




Endodermal Lineage (S1 to S0)




FOXA2**APOA1****AFP**

Epicardial Lineage (S3 to S5)




HAND1**TCF21****IGF2**

Myocardial Lineage (S3 to S4)

SMPX**TNNC1****TTN**




A**B****C****D**

Cardiac Progenitor






SHF Markers




Endoderm




FHF Markers

Cardiomyocyte Markers



A**B****C****D**

Atrial Markers



Ventricular Markers

